Document:

<Page>

                                                                    EXHIBIT 10.7

                             CONFIDENTIAL TREATMENT

                       COOPERATION AND LICENSING AGREEMENT

This Agreement (AGREEMENT) is entered into as of the 31st of December, 2001
(EFFECTIVE DATE) between NeoGenesis Pharmaceuticals, Inc., a Delaware
corporation (NEOGENESIS) and Aventis Pharma S.A., a corporation organized under
the laws of France and having a place of business at 20, avenue Raymond Aron,
92160 Antony, France (together with its Affiliates, AVENTIS), and sets forth the
terms and conditions that will apply to the provision by NeoGenesis to Aventis
of certain screening and analysis services.

                                   BACKGROUND

Aventis is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes of libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding affinity to and biological activity against targets
designated by Aventis from among the NeoGenesis libraries of mass-encoded small
molecule compounds and which have activity in bioassays or functional assays.
The terms and conditions set forth below shall govern the performance of such
collaborative effort.

1.  DEFINITIONS.

1.1 DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meaning set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition, CONTROL means, with respect to any
Person, the direct or indirect ownership of more than fifty percent (50%) of the
equity (or such lesser percentage which is the maximum allowed to be owned by a
foreign corporation, in a particular jurisdiction) having the power to vote on
or direct the management or policies of such Person.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against a specific target
protein.

     APPLICABLE LAWS means all laws, statutes, regulations and ordinances of any
Regulatory Authority, including without limitation the FD&C Act.

     AVENTIS INTELLECTUAL PROPERTY means, individually and collectively, (a) all
Inventions that are conceived, discovered, developed, generated, created, made
or reduced to practice or tangible medium of expression solely by employees or
consultants of Aventis at any time prior to the Effective Date or after the
Effective Date if such Inventions are not based upon or related to the
performance of the Program; (b) any tangible materials provided by Aventis to
NeoGenesis for use in the conduct of the Program, together with, where
applicable, any analogs, derivatives, fragments, progeny, sub-cellular
constituents or expression products thereof; (c) the Targets or the uses
thereof; and (d) the functional assays provided by Aventis under the Program.
The term Aventis Intellectual Property, however, does not include any know-how,
processes, information and data which is, as of the Effective Date or later
becomes, generally available to the public.

     AVENTIS PATENT RIGHTS means (a) those patents and patent applications
covering Aventis Intellectual Property and Program Intellectual Property owned
by Aventis that are Controlled by Aventis at any time during the term of this
Agreement which (i) relate to or otherwise would be infringed by the
manufacture, use, importation or sale of any Lead Compound or Product or (ii)
relate to Aventis Intellectual Property and (b) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts thereof.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

     COMMERCIALLY REASONABLE EFFORTS means, with respect to (i) any objective by
any party, reasonable, diligent, good faith efforts to accomplish such objective
as such party would normally use to accomplish a similar objective under similar
circumstances; and (ii) with respect to any objective relating to the
development or Commercialization of any Product by any party efforts and
resources normally used by such party with respect to a product owned by such
party or to which such party has similar rights which is of similar market
potential at a similar stage in the development or life of such product, taking
into account issues of safety, efficacy, the competitiveness of the marketplace,
the proprietary position of the product, the regulatory structure involved, and
profitability of the product.

     COMMERCIALIZATION means any and all activities of marketing, promoting,
distributing, offering for sale and selling a Product to a non-Affiliated third
party. When used as a verb, COMMERCIALIZE means to engage in Commercialization.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to all Aventis Intellectual Property
and all NeoGenesis Intellectual Property) disclosed to the other party pursuant
to this Agreement in written, electronic or other tangible medium and marked as
confidential, or if disclosed orally or displayed or disclosed in tangible
medium without a confidential marking, confirmed in a writing (describing the
information and referencing the place and date of such oral, visual, electronic
or written disclosure and the names of the persons to whom such disclosure was
made) within thirty (30) days of disclosure, except any portion thereof which:
(i) is known to the receiving party, as evidenced by the receiving party's
written records, before receipt thereof under this Agreement; (ii) is disclosed
to the receiving party by a third person who is under no obligation of
confidentiality to the disclosing party hereunder with respect to such
information and who otherwise has a right to make such disclosure; (iii) is or
becomes generally known in the trade through no fault of the receiving party; or
(iv) is independently developed by the receiving party, as evidenced by the
receiving party's written records, without access to such information.
Additionally any technical or financial information disclosed by either Party at
a meeting of the Steering Committee or disclosed through an audit report shall
constitute Confidential Information unless otherwise specified.

     CONTROL OR CONTROLLED means with respect to: (a) any item of information,
including, without limitation, Aventis Intellectual Property and NeoGenesis
Intellectual Property, or (b) any intellectual property rights, the possession
(whether by ownership or license, other than pursuant to this Agreement) by a
party or an Affiliate thereof of the ability to grant to the other party access
or a license as provided herein under such item of information or intellectual
property rights without violating the terms of any agreement or other
arrangements, between such party or its Affiliate and any third party, existing
before or after the Effective Date.

DERIVATIVE COMPOUNDS means any analog, homolog or isomer of a Lead Compound,
which has an IC50 value against the Screening Target of [*] micromolar or less,
which (a) results from a chemical synthesis program based on the Lead Compounds
or (b) is based on structure-activity data of the Lead Compound; PROVIDED, that
any such program or data is in respect of a target protein from other bacterial
or fungal organisms homologous in origin and biological function to the original
Screening Target.

     EMEA means the European Medical Evaluation Agency and any successor agency
thereto.

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938, as amended.

     FIELD means preventative, therapeutic and diagnostic uses in humans or
animals.

     FIRST COMMERCIAL SALE of Product(s) means any transfer for value in an
arms-length transaction to an independent third party distributor, agent or end
user in a country within the Territory after obtaining all necessary Regulatory
Approvals as may be necessary for such transfer in such country.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2

<Page>

     FORCE MAJEURE means any event beyond the control of the parties, including,
without limitation, failures of computers, computer-related equipment, hardware
or software, fire, flood, riots, strikes, epidemics, war (declared or undeclared
and including the continuance, expansion or new outbreak of any war or conflict
now in existence), embargoes and governmental actions or decrees.

     FTE means a full time equivalent person year (consisting of a total of 1880
hours per year) of scientific, technical or managerial work, carried out by one
or more employees or agents of NeoGenesis, who devotes a portion of his or her
time to performing further optimization activities as set forth herein.

     FTE RATE means the amount charged per FTE, such amount not to exceed [*].

     GOOD CLINICAL PRACTICE means the then current standards for clinical trials
for pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
clinical practice as are required by the European Union and other Regulatory
Authorities in countries in which the Product is intended to be sold, to the
extent such standards are not in contravention with United States Good Clinical
Practices.

     GOOD LABORATORY PRACTICE means the then current standards for laboratory
activities for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good laboratory practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Laboratory Practices.

     GOOD MANUFACTURING PRACTICE means the current standards for the manufacture
of pharmaceuticals, as set forth in the FD&C Act and applicable regulations
promulgated thereunder, as amended from time to time, and such standards of good
manufacturing practice as are required by the European Union and other
Regulatory Authorities in countries in which the Product is intended to be sold,
to the extent such standards are not in contravention with United States Good
Manufacturing Practices.

     IND means an investigational new drug application, as defined in the FD&C
Act and applicable regulations thereunder, or any equivalent document, filed
with the FDA and necessary for beginning clinical trials of any Product in
humans or any equivalent application or other documentation filed with any
Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Product in humans in that country.

     INVENTION(S) means all discoveries, inventions, know-how, trade secrets,
techniques, methodologies, modifications, improvements, works of authorship,
designs and data (whether or not protectable under patent, copyright, trade
secrecy or similar laws).

     LEAD COMPOUND means those Hit Compounds (or any analogs, homologs or
isomers of such Hit Compounds) that Aventis classifies as leads for further
research based on Aventis' good faith evaluation of the satisfaction of the
following criteria by such Hit Compound (or analogs, homologs or isomers of
such Hit Compound): (a) such Hit Compound is clearly optimized towards target
product profile; (b) SAR established on a series of more than [*] related
compounds including the Hit Compound and analogs, homologs or isomers of such
Hit Compound; (c) clear optimization potential for the Hit Compound (or
analogs, homologs or isomers of such Hit Compound) identified; (d)
satisfactory eADME [*] profile; (e) first in class in vivo PK; (f) other
preliminary in vivo data if accessible; (g) electrophysiology HERG assay when
appropriate; and (h) other secondary assays needed to pursue such Selected
Compound.

     MAJOR COUNTRY mean the United States, the United Kingdom, France, Germany
or Italy, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Product to be developed and/or Commercialized under this Agreement. When used as
a verb, MANUFACTURE means to engage in Manufacturing.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

     NDA means a new drug application as defined in the FD&C Act and applicable
regulations thereunder, and/or the non-U.S. equivalent thereof.

     NEOGENESIS INTELLECTUAL PROPERTY means, individually and collectively, (a)
all Inventions that are conceived, discovered, developed, generated, created,
made or reduced to practice or tangible medium of expression solely by employees
or consultants of NeoGenesis at any time prior to the Effective Date or after
the Effective Date (if such Inventions are not based upon or related to the
performance of the Program); (b) any tangible materials provided by NeoGenesis
to Aventis for use in the conduct of the Program, together with, where
applicable, any analogs, derivatives, fragments, progeny, sub-cellular
constituents or expression products thereof; and (c) the NeoMorph Screening
Library, the NeoMorph Focused Libraries, ALIS and QSCD. The term NeoGenesis
Intellectual Property, HOWEVER, does not include any know-how, processes,
information and data which is, as of the Effective Date or later becomes,
generally available to the public.

     NEOGENESIS PATENT RIGHTS means those (a) patents and patent applications
covering NeoGenesis Intellectual Property and Program Intellectual Property
owned by NeoGenesis listed in ATTACHMENT D, as ATTACHMENT D is amended from time
to time in accordance with Section 2.6 or Section 3.3, which are Controlled by
NeoGenesis; and (b) all divisionals, continuations, continuations-in-part,
reissues, extensions, supplementary protection certificates and foreign
counterparts thereof which are Controlled by NeoGenesis and are existing as of
the Effective Date or filed or issued during the term of this Agreement.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
derived from Primary Active Compounds identified by Aventis in bioassays or
functional assays

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, currently comprising approximately
10,000,000 different compounds.

     NET SALES means the aggregate amount invoiced by Aventis, its Affiliates or
any of its sublicensees to a third party distributor (who is not a sublicensee),
agent, contractor or end user for the sale of the Product (other than sales of
Products at cost by Aventis, its Affiliates or sublicensees to a third party for
use in a clinical study prior to regulatory approval of such Product) LESS
deductions selected as appropriate from: (a) credits, refunds and allowances
separately and actually credited to customers for defective, spoiled, damaged,
outdated, and returned Products, (b) offered and taken trade volume and cash
discounts and rebates in amounts customary to the trade, (d) sales, excise,
value added, turnover, use, and other like taxes, and customs duties, paid,
absorbed or allowed excluding net income tax, to the extent invoiced, (e)
compulsory payments and rebates accrued, paid or deducted pursuant to agreements
with third party payors or administrators (including but not limited to managed
care agreements) or government regulations, (f) outbound packing,
transportation, insurance and handling charges that are separately billed to the
customer or prepaid to the extent invoiced, and (g) price adjustments (including
retro-active price adjustments) separately and actually credited to customers.
The amounts of any deductions taken pursuant to clauses (a)-(g) shall be
determined from books and records maintained in accordance with GAAP,
consistently applied. Net Sales shall not include revenue received by Aventis
(or any of its Affiliates) from transactions with an Affiliate, where the
Product in question will be resold to an independent third-party distributor,
agent or end user by the Affiliate where such revenue received by the Affiliate
from such resale is included in Net Sales in accordance with Section 4.6.

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

     PRODUCT(S) means any product: (a) made up of, comprising or containing a
Lead Compound or a Derivative Compound; and (b) the development, manufacture,
use, or sale of which, absent the license granted to Aventis under Section 3.1
OR the rights assigned to Aventis under Section 3.2(d) of this Agreement, would
infringe the NeoGenesis Intellectual Property or NeoGenesis Patent Rights or
which makes use of any Program Patent Rights with respect to which NeoGenesis is
an inventor (in accordance under U.S. patent law).

     PROGRAM means, collectively, the screening program described in Paragraphs
1-6 of ATTACHMENT A (the SCREENING PROGRAM) and the optimization program
described in Paragraphs 7-8 of ATTACHMENT A (the HIT EXPLORATION PROGRAM) as the
same may be amended during the term of this Agreement by mutual agreement of the
parties acting through the Steering Committee (as defined below). The Screening
Program will be directed toward the discovery and development of Hits for the
Screening Targets and the Hit Exploration Program will be directed toward the
development of Lead Compounds for the Screening Targets.

     PROGRAM INTELLECTUAL PROPERTY means individually and collectively all
Inventions that are conceived, created, discovered, developed, generated, made
or reduced to practice or tangible medium of expression: (a) solely by one or
more employees or consultants of NeoGenesis at any time if such Inventions are
based upon or related to the performance of the Program; (b) jointly by one or
more employees or consultants of NeoGenesis and one or more employees or
consultants of Aventis at any time if such Inventions are based upon or related
to the performance of the Program; or (c) solely by one or more employees or
consultants of Aventis at any time if such Inventions are based upon or related
to the performance of the Program. Program Intellectual Property is listed in
ATTACHMENT B, which shall be amended from time-to-time to include new Program
Intellectual Property, in accordance with Section 3.3.

     PROGRAM PATENT RIGHTS means (a) those patents and patent applications, the
claim of which covers all or any part of Program Intellectual Property, and (b)
all divisionals, continuations, continuations-in-part, reissues, extensions,
supplementary protection certificates and foreign counterparts thereof.

     QSCD means Quantized Surface Complementary Diversity, a model proprietary
to NeoGenesis, in terms of which discrete chemical compliments to the surfaces
of a Target are defined.

     R&D PROGRAM means on a Lead Compound-by-Lead Compound basis the activities
necessary to be undertaken in connection with the research and development of
such Lead Compound prior to obtaining Regulatory Approval for a Product
(regardless of the country in which such activities are conducted).

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, marketing, promotion, pricing and sale of the
Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA and
the EMEA.

     SCREENING TARGET means a specific protein target - selected by Aventis for
which NeoGenesis will perform the Program and for which the screening fee
described in Section 4.1, the success payment described in Section 4.4, the
milestone payments described in Section 4.5 and royalties described in Section
4.6 are due from Aventis to NeoGenesis as specified in Section 4. An Excluded
Target is not a Screening Target for purposes of this Agreement until such time
as it becomes a Screening Target. The initial Screening Targets are identified
in ATTACHMENT C.

     TERRITORY means all the countries of the world.

1.2 OTHER  DEFINED  TERMS.  The  following  terms  shall have the  meanings
set forth in the section appearing opposite such term:

<Table>
         <S>                                         <C>
         AAA                                         Section 9.1
         AGREEMENT                                   Recitals

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

         AVENTIS                                     Recitals
         BANKRUPTCY CODE                             Section 3.1
         DISPUTE NOTICE                              Section 9.1
         EFFECTIVE DATE                              Recitals
         EXCLUDED TARGET                             Section 2.2
         FINAL TARGET REPORT                         ATTACHMENT A
         GENERIC RIGHTS                              Section 3.2
         HIT COMPOUND(S)                             ATTACHMENT A
         HIT EXPLORATION PROGRAM                     C.F. PROGRAM
         INDEMNIFIED PARTY(IES)                      Section 7.2
         INDEMNIFYING PARTY                          Section 7.2
         LICENSED TECHNOLOGY                         Section 3.1
         LOSSES                                      Section 7.2
         NEOGENESIS                                  Recitals
         PHASE II CLINICAL TRIALS                    Section 4.3
         PHASE III CLINICAL TRIALS                   Section 4.3
         PRELIMINARY COMPOUND                        ATTACHMENT A
         PRIMARY ACTIVE COMPOUNDS                    ATTACHMENT A
         PRIMARY ENDPOINT                            Section 4.3
         PROGRAM TERM                                Section 8.1
         SCREENING PERIOD                            Section 2.4
         SCREENING PROGRAM                           C.F. PROGRAM and Section 2.4
         SELECTED SERIES                             ATTACHMENT A
         STEERING COMMITTEE                          Section 2.7
</Table>

2.  SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION

2.1 SCOPE. Aventis shall select [*] protein targets as Screening Targets for the
Program. Aventis will disclose proposed Screening Targets to NeoGenesis using
the procedure specified in Section 2.2; PROVIDED, that Aventis will complete all
proposed Screening Target disclosure for the [*] initial Screening Targets not
later than [*] following the Effective Date.

2.2 DISCLOSURE OF TARGETS. During the Program Term, Aventis shall from time to
time disclose additional Targets to NeoGenesis in writing. Within [*] of each
disclosure of a proposed Target by Aventis, NeoGenesis shall notify Aventis as
to whether such Target is an Excluded Target. If NeoGenesis does not serve such
notice within the specified period, such Target shall not be deemed to be an
Excluded Target. NeoGenesis may deem a Target as an Excluded Target if on the
date NeoGenesis receives such proposed Target disclosure from Aventis: (i)
NeoGenesis is contractually prohibited from performing the screening
contemplated in this Agreement on such proposed Target, (ii) NeoGenesis has
received a request from a third party to provide screening on such proposed
Target and NeoGenesis reasonably expects to commence screening within [*] for
such third party or (iii) NeoGenesis has previously conducted screening on such
proposed Target for another party (each, an EXCLUDED TARGET). NeoGenesis will
promptly notify Aventis if an Excluded Target that was excluded pursuant to
Section 2.2(ii) does not become the subject of screening at NeoGenesis within
said [*] period and Aventis may have such Excluded Target deemed a Screening
Target with notice to NeoGenesis.

2.3 DELIVERY OF TARGET PROTEINS. Aventis shall deliver the Screening Targets
that have been accepted by NeoGenesis to NeoGenesis for screening within [*]
following acceptance by NeoGenesis in accordance with Section 2.2. Aventis shall
provide Screening Targets in the quantities and formats specified in ATTACHMENT
A. Aventis shall also provide NeoGenesis at the time of delivery with a written
description of the concentration and volume of the Screening Target. Aventis
shall deliver the Screening Targets Ex Works to NeoGenesis' Cambridge facility.

2.4 SCREENING PROGRAM. (a) NeoGenesis will use its ALIS method to screen the
NeoMorph Library for activity with respect to each Screening Target for purposes
of identifying potentially useful chemical compounds for further

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

evaluation and development. Screening will be performed pursuant to the
screening protocol for the Program set forth in ATTACHMENT A.

     (b) It is understood and agreed that while NeoGenesis will use Commercially
Reasonable efforts to complete the Screening Program for all three Screening
Targets within [*] following the Effective Date (the SCREENING PERIOD) and
complete the Hit Exploration Program for all [*] Screening Targets within [*]
following the Effective Date, in the event and to the extent that NeoGenesis has
not completed the Screening Program with respect to any Screening Target(s)
within such [*] period or completed the Hit Exploration Program within such [*]
period, NeoGenesis will continue to perform the applicable Program services
during the period following the expiration of the applicable period until
NeoGenesis completes the Program for each Screening Target submitted in
accordance with Sections 2.1-2.2 at no additional cost.

2.5 GRANT OF RESEARCH LICENSES. (a) Aventis hereby grants NeoGenesis a
nonexclusive, nontransferable, royalty-free license to use Aventis Intellectual
Property (including Aventis Patent Rights) solely for purposes of conducting the
Program and performing NeoGenesis' obligations under the Program. NeoGenesis
will not use Aventis Intellectual Property for any other purpose, without
Aventis' prior written permission. NeoGenesis shall not (i) grant, or attempt to
grant, a sub-license to use Aventis Intellectual Property to any Person without
the express written consent of Aventis, or (ii) modify the Screening Targets
supplied by Aventis, including, without limitation, the making of any analogs,
homologs or isomers thereof. In the event that NeoGenesis does not consume all
of the Screening Targets supplied by Aventis in performance of the Program,
NeoGenesis will upon completion of the Program, return to Aventis any quantities
of such Screening Target(s) and any analogs, homologs or isomers thereof.

     (b) NeoGenesis hereby grants Aventis a nonexclusive, nontransferable,
royalty-free license to use NeoGenesis Intellectual Property (including
NeoGenesis Patent Rights) solely for purposes of conducting the Program and
performing Aventis' obligations under the Program. Aventis will not use
NeoGenesis Intellectual Property for any other purpose, without NeoGenesis'
prior written permission. Aventis shall not grant, or attempt to grant, a
sub-license to use NeoGenesis Intellectual Property to any Person without the
express written consent of NeoGenesis. In addition, Aventis shall not analyze
any Preliminary Compounds or Active Compounds or Primary Active Compounds
structurally or otherwise seek to derive the structure of such Preliminary
Compounds or Active Compounds or Primary Active Compounds until such time as
Aventis designates Primary Active Compounds as Hit Compounds in accordance with
the procedure specified in ATTACHMENT A.

2.6 SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Program to enable it
to furnish complete and accurate information to Aventis regarding the Program
activities and results, including all Preliminary Compounds, Active Compounds
and NeoMorph Focused Libraries identified in the Program and all NeoGenesis
Program Intellectual Property developed during the Program. All such written
records of NeoGenesis shall be open to inspection by Aventis during normal
business hours upon reasonable prior notice.

     (b) NeoGenesis shall provide Aventis with reasonably-detailed written
reports describing the results of the research performed pursuant to the Program
including all Preliminary Compounds, Active Compounds and NeoMorph Focused
Libraries identified in the Program. Such reports shall be delivered to Aventis
at least monthly during the Program. NeoGenesis will deliver a Final Target
Report and a Candidate Lead Compound Report (as defined in ATTACHMENT A) with
respect to the Program work performed on each Screening Target including a
description of all the Preliminary Compounds, Primary Active Compounds and
NeoMorph Focused Libraries identified during the Program with respect to such
Screening Target.

2.7 STEERING COMMITTEE. (a) A Steering Committee (STEERING COMMITTEE) shall be
responsible for the oversight of the day-to-day management of the Program. The
Steering Committee shall consist of four members, two members to be appointed by
each of NeoGenesis and Aventis. Each party may, with notice to the other,
substitute any of its members serving on the Steering Committee. The initial
Aventis members shall be John Hodgson and Norbert Dereu and the initial
NeoGenesis members shall be Peter Lomedico and Huw Nash. Aventis shall have the
right to appoint one of its members to be the chairperson of the Steering
Committee.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

     (b) The Steering Committee shall be responsible for the management and
conduct of the Program and shall in particular: (i) consider, review and amend
the Program from time to time in such manner as may be appropriate; (ii) monitor
progress of the Program; (iii) report regularly to the management of both
parties upon the progress of the Program; and (iv) be the initial medium for
transfer of information between the parties.

     (c) The Steering Committee shall hold meetings as mutually agreed by the
parties (but in no event less than four (4) times during the Screening Period)
to review the Program. The first meeting of the Steering Committee shall be held
within forty-five (45) days of the Effective Date and shall be held in
Cambridge, MA. Thereafter, meetings may be held by telephone or video conference
if requested by either party in writing to the other, PROVIDED that the parties
shall meet in person at least two (2) times during the Screening Period. Draft
Minutes of all meetings setting forth decisions of the Steering Committee
relative to the Screening Process shall be prepared by the Chairman, or his
designate and circulated by the Chairman to both parties within fifteen (15)
days after each meeting, but minutes shall not become official until approved by
both parties (which approval the parties shall use reasonable efforts to give
within thirty (30) days of receipt of such minutes).

     (d) The quorum for Steering Committee meetings shall be two, provided there
is at least one member from each of NeoGenesis and Aventis present. Aventis and
NeoGenesis shall each have one vote at the Steering Committee. The Steering
Committee will render decisions by unanimous vote. Disagreements among the
Steering Committee regarding the Program will be resolved via good-faith
discussions; PROVIDED, that in the event of a disagreement that cannot be
resolved within fifteen (15) days after the date on which the disagreement
arose, the matter shall be referred to Aventis' Head of Drug Innovation and
Approval for France and NeoGenesis' Chief Executive Officer or their respective
designees. Thereafter, if any such disagreement is not resolved within thirty
(30) days, then Aventis will have the right to make the final decision.

2.8 LEAD COMPOUNDS. (a) Within [*] following the completion of the evaluation
described in Paragraph 8 of ATTACHMENT A, the Steering Committee shall make a
recommendation to Aventis on the nomination of Lead Compounds. Within [*] from
receipt of the Steering Committee's recommendation, Aventis shall notify
NeoGenesis whether it will designate any Lead Compounds for such Screening
Target, or whether it wishes further optimization work with respect to such
Selected Series. If Aventis does not designate any Lead Compound(s) against a
particular Screening Target within such period or initiate further optimization
work with respect to such Selected Series within such period, the rights granted
Aventis shall terminate and be of no further force or effect with respect to
Lead Compounds and/or Products against the applicable Screening Target, and no
further payment from Aventis shall be due with respect to such Screening Target.
If Aventis does identify any Lead Compounds, such Lead Compounds will be subject
to the license granted Aventis and shall no longer be available to NeoGenesis or
any third party in any NeoGenesis compound library, including its mass encoded
NeoMorph compound library or in any other manner. There shall be no limit on the
number of Lead Compounds that may be taken; PROVIDED, all such Lead Compounds
have a binding affinity of [*] and demonstrated activity in the Screening
Target-based biochemical/functional assays with [*]. If Aventis does not
identify any Lead Compounds but does initiate further optimization work with
respect to such Selected Series, such Selected Series compounds will remain
subject to Section 3.2 and Section 3.3(a) for a period of not longer than [*]
during which optimization may be performed and Aventis will pay NeoGenesis in
accordance with Section 4.2 as if the Hit Exploration Program were being
pursued. If Aventis does not designate Lead Compounds by the end of such [*]
period, Aventis will be deemed to have not designated Lead Compounds in respect
of such Screening Target.

     (b) Within thirty (30) days following receipt of notification from Aventis
identifying Lead Compounds, NeoGenesis shall amend ATTACHMENT D to identify any
applicable NeoGenesis Patent Rights not previously identified to Aventis.

2.9 PRODUCT DEVELOPMENT. Aventis, at its sole expense, shall be responsible for
and shall use its Commercially Reasonable Efforts to conduct the R&D Program
related to Lead Compounds and Products and to develop and obtain Regulatory
Approvals for Products in each of the Major Countries; provided that, in the
reasonable exercise of Aventis discretion, development in each such Major
Country is commercially expedient.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

2.10 MANUFACTURE OF PRODUCT. Aventis, at its sole expense, shall be responsible
for and shall use its Commercially Reasonable Efforts to Manufacture the
Products in accordance with the Regulatory Approvals, Applicable Laws, Good
Laboratory Practices and Good Manufacturing Practices.

2.11 REGULATORY MATTERS. Aventis, at its sole expense, shall be responsible for
the preparation and filing, with the appropriate Regulatory Authorities, of all
documents that are necessary to conduct clinical studies of Products and
Regulatory Approval applications that are necessary to market and sell Products.
Aventis shall use Commercially Reasonable Efforts to file Regulatory Approval
applications in the Major Countries. Simultaneously with the submission of each
such regulatory filing, Aventis shall notify NeoGenesis, in writing, that such
regulatory filing has been made. Aventis shall be responsible for reporting all
adverse events associated with any Product to the appropriate Regulatory
Authorities in accordance with Applicable Laws.

2.12 MARKETING AND SALE. Aventis, at its sole expense, shall be responsible for
the Commercialization of Products in the Territory and shall use its
Commercially Reasonable Efforts to Commercialize each Product in each of the
Major Countries. Aventis shall be responsible for establishing the price of each
Product sold by or on behalf of it pursuant to this Agreement.

2.13 THIRD PARTY LICENSES. Aventis, at its sole expense, shall be responsible
for obtaining any and all licenses from third parties necessary or desirable to
perform the R&D Program and/or to Commercialize any Product; PROVIDED, that the
provisions of Section 4.4(b) may result in a reduction in the royalties payable
to NeoGenesis with respect to certain third party licenses.

2.14 COMPLIANCE WITH LAW. Aventis shall conduct the R&D Program and conduct its
Manufacturing operations in a safe and prudent manner, in compliance with all
Applicable Laws (including, but not limited to, occupational safety and health,
public safety and health, protecting the environment, the disposal of wastes,
Good Clinical Practices, Good Laboratory Practices and Good Manufacturing
Practices), and in compliance with all applicable provisions of this Agreement.
Aventis shall obtain all necessary registrations and permits pertaining to
activities contemplated by this Agreement. NeoGenesis shall conduct all
activities contemplated by this Agreement in accordance with all Applicable
Laws, including, but not limited to, occupational safety and health, public
safety and health, protecting the environment, the disposal of wastes and Good
Laboratory Practices.

2.15 PERIODIC REVIEW. Aventis and NeoGenesis shall periodically meet, at such
times and places as are mutually agreed upon, for Aventis to provide NeoGenesis
with an update on the status of the progress of Aventis' R&D Program and
Commercialization of each Product, PROVIDED, HOWEVER, that such meetings shall
occur no more than twice per calendar year unless the parties agree, in writing,
to meet more often. Aventis and NeoGenesis shall each be responsible for its own
expenses incurred in connection with attending such meetings.

3.  LICENSE; PROPRIETARY RIGHTS

3.1 GRANT OF LICENSE. (a) Subject to the terms and conditions of this Agreement,
including the payment of all applicable fees, NeoGenesis hereby grants to
Aventis, and Aventis hereby accepts, an exclusive, worldwide, right and license,
within the Territory, to use the NeoGenesis Intellectual Property and NeoGenesis
Patent Rights with application to the Field (collectively, the LICENSED
TECHNOLOGY) to the extent necessary or useful to research, develop, make, have
made, use, distribute for sale, promote, market, offer for sale, sell, have
sold, import and export Lead Compounds and Products. Aventis may grant
sublicenses of its rights under this Section 3.1; PROVIDED that Aventis: (i)
obtains the written agreement of each non-Affiliated sublicensee to be subject
to the same obligations as is Aventis under Sections 2.14, 2.15, 3.1(c), 3.2,
4.4-4.8, 5.2 and 8.3(c) (last sentence) of this Agreement (or substantially
identical provisions) and (ii) shall remain responsible for the performance of
all of its obligations under this Agreement, whether such obligations are
performed by Aventis, its Affiliates or any of its sublicensees. Aventis shall
also ensure that all sublicensees are required to indemnify NeoGenesis with
respect to the matters that are addressed in Section 7.2(b) and Section 7.3(b)
(it being further understood that NeoGenesis need not be identified by name).

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

     (b) The license granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that
Aventis may elect to retain and may fully exercise all of its rights and
elections under the Bankruptcy Code PROVIDED, that it abides by the terms of
this Agreement.

     (c) Aventis shall mark or have marked all containers or packages of
Products that are the subject of the license granted under this Section 3.1 in
accordance with the patent marking laws of the jurisdiction in which such
Products are manufactured, used or sold.

3.2 RETAINED RIGHTS. (a) This Agreement does not convey to NeoGenesis any
ownership rights in any Aventis Intellectual Property by implication, estoppel
or otherwise except for the rights expressly granted in Section 2.5. Title to
the Aventis Intellectual Property shall at all times remain vested in Aventis.
This Agreement does not convey to Aventis any ownership rights in any NeoGenesis
Intellectual Property by implication, estoppel or otherwise except for the
rights expressly granted in Section 3.1 and assigned in Section 3.2(d). Title to
the NeoGenesis Intellectual Property shall at all times remain vested in
NeoGenesis. Title to and any interest in Program Intellectual Property described
in clause (a) of the Program Intellectual Property definition (including
corresponding Program Patent Rights) shall be the property of NeoGenesis and is
included in the definition of NeoGenesis Intellectual Property. Title to and any
interest in Program Intellectual Property described in clause (b) of the Program
Intellectual Property definition (including corresponding Program Patent Rights)
shall be jointly held by Aventis and NeoGenesis. Title to and any interest in
Program Intellectual Property described in clause (c) of the Program
Intellectual Property definition (including corresponding Program Patent Rights)
shall be the property of Aventis and is included in the definition of Aventis
Intellectual Property. Notwithstanding any of the foregoing, Program
Intellectual Property, regardless of inventorship, shall be: (i) the property of
NeoGenesis if such Program Intellectual Property is directly related to the
NeoMorph Screening Library (except as described in Section 3.2(a)(ii)(2) below),
ALIS screening technology or QSCD; and (ii) the property of Aventis (1) if such
Program Intellectual Property is directly related to the Screening Targets or
the uses thereof or to Aventis' functional or secondary assays, or to the
Products, or (2) if such Program Intellectual Property relates to the Lead
Compounds and analogs, homologs and isomers thereof or the Products.

     (b) If required, patent counsel mutually acceptable to the parties and
selected by the Steering Committee in accordance with Section 3.3(c) shall
determine inventorship of all Program Intellectual Property (including Program
Patent Rights) that arises from the transactions contemplated by this Agreement
in accordance with U.S. patent law (and other U.S. intellectual property law)
when determining whether such intellectual property is (i) Aventis Intellectual
Property or (ii) NeoGenesis Intellectual Property or (iii) whether Program
Intellectual Property (including Program Patent Rights) is jointly owned or is
owned solely by NeoGenesis or owned solely by Aventis.

     (c) NeoGenesis shall retain the following rights with respect to the
following NeoGenesis Intellectual Property and Program Intellectual Property
(including Program Patent Rights):

         (i) NeoGenesis shall continue to use its NeoMorph Screening Library to
         screen target proteins for other parties; PROVIDED, that any Screening
         Targets screened by NeoGenesis on behalf of Aventis, shall not be
         screened for a third party or internally at NeoGenesis (nor shall
         NeoGenesis research, develop, make, use or sell any products active
         against such Screening Targets) during the Program and for a period of
         [*] following the completion of all work by NeoGenesis under the
         Program. It is understood and acknowledged by NeoGenesis that the
         restrictions imposed by this paragraph will operate independently of
         and in addition to any patent rights that Aventis may hold in respect
         of any Screening Target.

         (ii) NeoGenesis shall retain all rights and may continue to use
         Preliminary Compounds created as part of the Program but not selected
         as Primary Active Compounds and Primary Active Compounds not selected
         as Hit Compounds; PROVIDED, HOWEVER, that such Preliminary Compounds
         and Primary Active Compounds (A) may not be used against the Screening
         Targets and (B) shall only be used in the event and to the extent they
         result from use of the primary mass-encoded NeoMorph Screening Library
         to screen target proteins for other parties. Notwithstanding the
         foregoing, it is understood and agreed that NeoGenesis shall mask all
         Preliminary Compounds created as part of the Program until such time as
         Aventis selects Primary Active

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

         Compounds in accordance with paragraph 3 of ATTACHMENT A and shall
         mask all Primary Active Compounds created as part of the Program until
         such time as Aventis selects Hit Compounds in accordance with
         paragraph 6 of ATTACHMENT A and shall mask all Hit Compounds created
         as part of the Program until such time as Aventis selects Lead
         Compounds in accordance with Section 2.8.

     (d) In addition to the license granted under Section 3.1 with respect to
Licensed Technology, NeoGenesis hereby assigns and agrees to assign to Aventis
all of NeoGenesis' right, title and interest in all Lead Compounds designated by
Aventis in accordance with Section 2.8. Such assigned Lead Compounds and the
corresponding NeoGenesis Patent Rights shall, from the date of assignment by
NeoGenesis, be treated as Aventis Patent Rights for purposes of this Agreement
(including Section 3.3(c) and Section 3.4) and such assigned Lead Compounds and
the corresponding NeoGenesis Intellectual Property shall, from the date of
assignment by NeoGenesis, be treated as Aventis Intellectual Property for
purposes of this Agreement (including Section 3.3(c) and Section 3.4); PROVIDED,
that notwithstanding any provision of this Agreement to the contrary, Aventis
shall remain obligated to pay NeoGenesis in respect of all such assigned Lead
Compounds (and any related Products) the milestone fees and royalties due
NeoGenesis under Section 4.3 and Section 4.4 of this Agreement. The date of
assignment with respect to the designated Compounds shall be the date Aventis
notifies NeoGenesis that a particular Hit Compound has been designated as a Lead
Compound and pays the fee for such Lead Compound specified in Section 4.3(a)(i).

     (e) If, at any time during the applicable license term, NeoGenesis has or
obtains any patent or other proprietary right in any Program Intellectual
Property (by ownership or license) that could be asserted to prevent Aventis
from practicing the Aventis Intellectual Property or Program Intellectual
Property owned by Aventis to research, develop, make and have made, use,
distribute for sale, promote, market, offer for sale, sell, have sold, import
and export compounds, NeoGenesis will grant Aventis a non-exclusive, worldwide,
perpetual license (or sublicense, as the case may be), with the right to
sublicense, to such patent or other proprietary right and Aventis will pay
NeoGenesis royalties on sales of such compounds as described under Section 4.4
to the extent necessary or useful to practice the license granted under Section
3.1; provided, however, that the foregoing shall not be construed to grant
Aventis any license to utilize NeoGenesis' proprietary mass encoded NeoMorph
compound library, ALIS screening technology or QSCD except as otherwise
expressly set forth in this Agreement.

     (f) Aventis hereby grants NeoGenesis an irrevocable, exclusive (except as
to Aventis as described below in this Section 3.2(f)), fully-paid, perpetual
license to any Program Intellectual Property described in Section 3.2(a)(ii)(2),
except that in each case Aventis will retain exclusive rights in such Program
Intellectual Property (the GENERIC RIGHTS) to the extent necessary or useful to
research, develop, make and have made, use, distribute for sale, promote,
market, offer for sale, sell, have sold, import and export Lead Compounds and/or
Products.

     (g) Neither party shall use Program Intellectual Property owned by the
other party unless exclusively licensed back to such party by the other party
(pursuant to Section 3.2(f)) or Confidential Information of the other party
outside of the performance of the Program or except as otherwise permitted in
the Agreement.

3.3 DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Aventis shall
promptly disclose to the other knowledge of any Invention that constitutes
Program Intellectual Property; such Program Intellectual Property will be added
to ATTACHMENT B (and ATTACHMENT D if applicable) and will be subject to the
provisions of this Agreement. Within forty-five (45) days following the date of
such disclosure regarding the existence of particular Program Intellectual
Property that is jointly owned, the parties shall confer as to appropriate
protection for such Program Intellectual Property. Notwithstanding the provision
of this Section 3.3, no party shall file, prosecute and maintain any Program
Patent Right without the other party's prior written consent before the date
specified in Section 2.8 for Aventis' notice of Lead Compounds.

(b) NeoGenesis shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at NeoGenesis' sole expense, each of the NeoGenesis
Patent Rights throughout the Territory. NeoGenesis shall promptly furnish or
have furnished to Aventis copies of all patents, patent applications,
substantive patent office actions, substantive responses received or filed in
connection with such patents and patent applications (other than patents and
patent applications covering solely NeoGenesis Intellectual Property that is not
licensed to Aventis under Section 3.1 or assigned to Aventis under Section
3.2(d)). Aventis may itself or through its attorney offer comments and
suggestions with

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

respect to the matters that are the subject of this Section 3.3(b) and
NeoGenesis agrees to consider such comments and suggestions; PROVIDED that
nothing herein shall obligate NeoGenesis to adopt or follow such comments or
suggestions. Aventis shall cooperate in the preparation, filing, prosecution and
maintenance of any and all patent applications and patents included in Program
Intellectual Property owned by NeoGenesis. NeoGenesis shall promptly provide
notice to Aventis as to all matters that come to its attention that may affect
the preparation, filing, prosecution or maintenance of any patents or patent
applications within the Program Intellectual Property owned by NeoGenesis.
NeoGenesis shall not seek patent protection that covers generic claims to any
class of compounds developed in the course of the Program until such time as
Aventis has designated Lead Compounds in respect of such class of compounds or
until the period of time for such designation expires with respect to the
Selected Compounds derived from such class of compounds. In the event that
NeoGenesis elects not to file for patent protection under the NeoGenesis Patent
Rights or elects not to prosecute or maintain a patent or patent application
under the NeoGenesis Patent Rights it shall notify Aventis of such decision at
least forty-five (45) days prior to the due date of any action or payment due.
Aventis shall have the right, but not the obligation to assume the
responsibility therefor then at its own cost and expense. If appropriate, such
patents and patent applications rights should then be assigned to Aventis;
PROVIDED, Aventis reimburses NeoGenesis for its' documented patent costs in
respect of such assigned patents and patent applications.

(c) Aventis shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at Aventis' sole expense (except as provided below),
each of the Aventis Patent Rights throughout the Territory. Aventis shall
promptly furnish or have furnished to NeoGenesis copies of documents relevant to
Generic Rights and provide NeoGenesis with the opportunity to review and comment
on patent decisions made by patent counsel. NeoGenesis shall be responsible for
[*] of all costs relating to the preparation, filing, prosecution and
maintenance of any and all patent applications and patents covering Generic
Rights. NeoGenesis shall cooperate in the preparation, filing, prosecution and
maintenance of any and all patent applications and patents included in Program
Intellectual Property owned by Aventis. Aventis shall promptly provide notice to
NeoGenesis as to all matters that come to its attention that may affect the
preparation, filing, prosecution or maintenance of any patents or patent
applications within the Program Intellectual Property owned by Aventis relating
to Generic Rights.

3.4 ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Intellectual Property and NeoGenesis Patent Rights but
excluding Licensed Technology. Aventis shall be solely responsible for the
defense and enforcement of Aventis Intellectual Property and Aventis Patent
Rights.

     (b) Except as otherwise provided in Section 3.4(a), Aventis shall have the
first option to pursue any enforcement or defense of Licensed Technology;
PROVIDED, that Aventis pays all costs and expenses related to the same, keeps
NeoGenesis reasonably informed of its progress and provides NeoGenesis with
copies of any documents related to such proceedings and reasonable notice of all
proceedings relating to same. Aventis' costs in prosecuting such matters shall
be subject to reimbursement in accordance with Section 3.4(d). Aventis shall
notify NeoGenesis of its decision to exercise its right to enforce Licensed
Technology as soon as possible, and shall bring an enforcement action not later
than sixty (60) days (forty five (45) days in the case of an action brought
under the Hatch-Waxman Act) following its discovery or receipt of notice of the
alleged infringement.

     (c) If Aventis does not exercise its option to enforce or defend any
Licensed Technology within sixty (60) days (forty five (45) days in the case of
an action brought under the Hatch-Waxman Act) or (within ninety (90) days of
commencing to prosecute any enforcement or defense action) Aventis and
NeoGenesis have not otherwise agreed not to pursue such infringement for
business reasons, and Aventis (i) has not persuaded the alleged infringer to
desist, (ii) is not diligently pursuing an infringement action or diligently
defending the validity or enforceability of Licensed Technology at issue, as
determined by NeoGenesis in its reasonable discretion, or (iii) has not provided
NeoGenesis with evidence of bona fide negotiations of an acceptable sublicense
agreement with the alleged infringer, then NeoGenesis shall have the right to
pursue the alleged infringer or take control of any action initiated by Aventis
at NeoGenesis' own expense. In any such case, Aventis will substitute NeoGenesis
as party plaintiff for purposes of pursuing any alleged infringer.

     (d) Any recovery of damages with regard to Licensed Technology in any suit
handled by one party pursuant to Section 3.4(b) or Section 3.4(c) shall be
applied first in satisfaction of any unreimbursed expenses and legal fees of

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

the litigant relating to the suit or settlement thereof. The balance of any
recovery shall be distributed (i) first to Aventis in an amount equal to its
lost profits or a reasonable royalty on the sales of the infringer (whichever
measure of damages the court shall have applied), and (ii) then to NeoGenesis in
an amount equal to the royalties due NeoGenesis based on such sales (if the
court applies a sales of the infringer measure of damages) or a reasonable
approximation of the royalties that Aventis would have owed to NeoGenesis on
sales of Products that Aventis lost to the infringer (if the court applies a
lost profits measure of damages). The balance, if any, remaining after Aventis
has been compensated for lost profits or lost sales and NeoGenesis has been
compensated for lost royalties shall be paid to Aventis. No settlement, or
consent judgment or other voluntary final disposition of any suit regarding
Licensed Technology may be entered into without the consent of the other party,
which consent shall not be unreasonably withheld.

     (e) Notwithstanding the provisions of Section 3.4(b), in the event that a
declaratory judgment action alleging invalidity or non-infringement of any of
the patents within Licensed Technology that are within NeoGenesis Patent Rights
but are not within jointly owned Program Intellectual Property, NeoGenesis shall
have the first option, within sixty (60) days after notification of same, to
assume defense of the action concerning its own technology at its expense, but
Aventis shall be entitled to participate in such action, at its own expense.

     (f) In any infringement suit as either party may institute to enforce
Licensed Technology, or in any declaratory judgment action alleging invalidity
or non-infringement of any Licensed Technology brought against NeoGenesis or
Aventis, the other party shall, at the request and expense of the party
initiating or defending the suit or action, cooperate and assist in all
reasonable respects, having its employees testify when requested and making
available relevant records, papers, information, specimens and the like.

4.  PRICING; PAYMENT

4.1 SCREENING FEE. Aventis shall pay NeoGenesis a fee of [*] for each Screening
Target screened pursuant to the Program that is a non-protein/protein
interaction Screening Target and a fee of [*] for each Screening Target screened
pursuant to the Program that is a protein/protein interaction Screening Target.
Such fee shall be payable with respect to the first [*] Screening Targets in two
installments: the first installment of [*] on the Effective Date and the second
installment consisting of the remaining balance due in accordance with the
immediately preceding sentence within [*] of "completion of screening" against
all [*] of the Screening Targets. "Completion of screening" for each Screening
Target shall be deemed to occur upon delivery of Hit Compounds for such
Screening Target to Aventis (or, if Aventis does not designate any Hit
Compound(s) for such Screening Target, within [*] of receipt of the Final Target
Report for such Screening Target, then at the end of such [*] period). Any work
conducted for further optimization and evaluation of Hit Compounds to Selected
Series or to Lead Compounds will be carried out on FTE basis in accordance with
Section 4.2 and Paragraphs 7-8 of ATTACHMENT A.

4.2 HIT EXPLORATION FEE. Commencing on the first anniversary of the Effective
Date, but not prior to the date Aventis commences optimization of Hit Compounds
resulting from the Screening Program (whether such optimization is performed by
NeoGenesis or Aventis), Aventis will provide NeoGenesis with [*] of funding, at
the FTE Rate and payable in equal quarterly installments over such [*], for at
least [*] full time FTE positions per year to facilitate the performance by
NeoGenesis of the Hit Exploration Program. Aventis may increase such Hit
Exploration Program funding for up to an aggregate [*] FTE positions per annum.
Such FTE personnel shall, at the direction of the Steering Committee, perform
optimization and evaluation of Hit Compounds to Selected Series or to Lead
Compounds; PROVIDED, that if the Steering Committee does not direct the
expenditure of all FTE funding on such optimization and evaluation services in
any year of such [*] period, Aventis may use such FTE funding to fund screening
of up to [*] additional Screening Target during each year of such [*] period;
such additional Screening target to be proposed by Aventis using the procedure
specified in Section 2.2.

4.3 MILESTONES. (a) Aventis will pay NeoGenesis milestone payments in respect of
Products as specified in this Section 4.3.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

         (i)  Within thirty (30) days following the date on which Aventis
              identifies each Lead Compound (if any), Aventis will pay
              NeoGenesis [*]. Aventis shall promptly notify NeoGenesis of the
              decision to nominate a Lead Compound.

         (ii) Within thirty (30) days following the date on which Aventis files
              the first IND in a Major Country, Aventis will pay NeoGenesis [*].
              Aventis shall promptly notify NeoGenesis of the decision to
              initiate such toxicology studies.

         (iii)Within thirty (30) days following the date on which the first
              administration or dosing of any Product occurs in a Major Country
              in the first Phase II Clinical Trials relating to such Product,
              Aventis will pay NeoGenesis [*]. PHASE II CLINICAL TRIALS means
              any human clinical trials for which a Primary Endpoint is a
              preliminary determination of safety, biological activity, efficacy
              or dose ranges in patients with the disease target being studied
              as required by the relevant Regulatory Authorities. PRIMARY
              ENDPOINT means, with respect to a Phase II Clinical Trial, the
              point at which POSITIVE statistical significance has been achieved
              with respect to the primary endpoint specified in the protocol for
              such trial.

         (iv) Within thirty (30) days following the date on which the first
              administration or dosing of any Product occurs in a Major Country
              in the first Phase III Clinical Trials relating to such Product,
              Aventis will pay NeoGenesis [*]. PHASE III CLINICAL TRIALS means
              any clinical studies of any Product in human patients with the
              disease target being studied to determine safety and efficacy of a
              Product in patients as required by the relevant Regulatory
              Authorities.

         (v)  Within thirty (30) days following the date on which Aventis
              receives an NDA approval from the FDA permitting the manufacture
              and sale of a Product, or a comparable Regulatory Approval for
              another Major Country, Aventis will pay NeoGenesis [*].

     (b) Milestones identified in Section 4.3(a)(i)-(v) shall be due only for
the first Product that is active against a particular Screening Target,
regardless of (i) the number of Products that are active against such Screening
Target that are identified by the Program or developed and/or commercialized by
Aventis, and (ii) the number of times a Product hits such milestone (e.g., if
different indications are pursued for the same Product); PROVIDED, that if the
first Product that is active against a Screening Target does not achieve any
milestone(s), such non-achieved milestones shall be paid on any subsequent
Product that is active against such Screening Target and that achieves such
milestone. On the date any one milestone with respect to a Product is achieved,
all lower numbered unachieved milestones shall be deemed to have been achieved
with respect to that Product and shall be paid (except to the extent they have
previously been paid with respect to another Product active against the relevant
Screening Target).

4.4 ROYALTIES. (a) Not later than [*] following each March 31, June 30,
September 30 and December 31 commencing with the First Commercial Sale of
Products that are active against Screening Targets in any country, Aventis shall
pay to NeoGenesis royalties by country for the most recent three-month period
then ended, equal to (i) [*] of Net Sales. Aventis shall pay royalties with
respect to each Product on a country by country basis (1) until the expiration
or revocation or complete rejection of the last to expire or to be revoked or to
be completely rejected of any NeoGenesis Patent Right (including those
NeoGenesis Patent Rights assigned to Aventis pursuant to Section 3.2(d))
covering such Product in the country in which the Product is manufactured or
sold, or (2) if no NeoGenesis Patent Right (including those NeoGenesis Patent
Rights assigned to Aventis pursuant to Section 3.2(d)) exists in the relevant
country covering the manufacture, use or sale of the relevant Product, until [*]
from the First Commercial Sale of such Product in such country.

     (b) If Aventis is required to make payments (including, without limitation,
royalties, option fees or license fees) to one or more third parties to obtain
licenses or similar rights under patents owned by a third party to avoid
infringement by any Product of such third party(ies) patent-protected
technology, then Aventis may, beginning from the date of such third party
payments, deduct fifty percent (50%) of the amount of such third party payments
in any calendar quarter from the royalties payable to NeoGenesis in such
calendar quarter; provided that such deductions

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

shall not exceed one half (50%) of the applicable royalty rate specified in
Section 4.4(a) with respect to such Product.

4.5 REMITTANCE. (a) All royalties and milestone payments required under this
Section 4 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales are made. For the purpose of
computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
simple average of the closing mid-point rates for the last business day of each
month of the calendar quarter for buying United States Dollars for the calendar
quarter in which such sales were made. The "closing mid-point rates" found in
the "Dollar spot forward against the Dollar" table published by THE FINANCIAL
TIMES or any other publication as agreed to by the parties shall be used as the
source of spot rates to calculate the average as defined in the preceding
sentence.

     (b) In the event that any payment due NeoGenesis under this Agreement is
not made when due, the amount due shall accrue interest beginning on the fifth
day following the final date on which such payment was due, calculated at the
annual rate equal to two percent (2%) above the 30-day LIBOR for U.S. dollars
reported in the WALL STREET JOURNAL for the due date, calculated from the due
date until paid in full. Such payment when made shall be accompanied by all
interest so accrued. Said interest and the payment and acceptance thereof shall
not negate or waive the right of NeoGenesis to any other remedy, legal or
equitable, to which it may be entitled because of the delinquency of the
payment.

     (c) If at any time legal restrictions within any country in the Territory
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by Aventis of any royalties owed
by Aventis to NeoGenesis in respect of sales in such country is prevented,
Aventis shall make payment through any lawful means or methods that may be
available as Aventis shall reasonably determine. If royalties in any country
cannot be remitted within three (3) months after the end of the relevant royalty
period then Aventis shall pay NeoGenesis in the local currency of such country
by deposit of the relevant royalties in a bank account in such country
designated by NeoGenesis.

4.6 RECORDS. Aventis, its Affiliates and sublicensees shall keep and maintain
for a period of at least three (3) years from the date of each payment of
royalties, records (prepared in accordance with GAAP) sufficient to determine
the amounts of Net Sales and payments due under Section 4.4. Within forty-five
(45) days following each March 31, June 30, September 30 and December 31 in
which payments are due under Section 4.4, Aventis shall provide NeoGenesis with
a report including at least: (a) actual Net Sales, by country in local currency;
(b) the currency conversion rate used and U.S. dollar-equivalent of such sales;
(c) the calculation of royalties thereon; and (d) the total royalties so
computed and due NeoGenesis. Such reports shall be submitted to NeoGenesis
whether or not any sales of Product have been made during such period. Upon
delivery of the report due for the period ending December 31 of each year,
Aventis shall also report to NeoGenesis the aggregate royalties due NeoGenesis
for the entire preceding year.

4.7 INSPECTION. Aventis and its Affiliates shall, and Aventis shall provide in
any agreements with any sublicensees that such sublicensees shall, each make its
records available for inspection by an independent certified public accountant,
appointed by NeoGenesis and reasonably acceptable to Aventis, during regular
business hours at such place or places where such records are customarily kept,
upon reasonable notice from NeoGenesis, to verify the accuracy of the reports
and payments. Such inspection right shall not be exercised more than once in any
calendar year nor more than once with respect to sales of Products in any given
payment period. NeoGenesis agrees to hold in confidence all information
concerning royalty payments and reports, and all information learned in the
course of any audit or inspection, except to the extent necessary for NeoGenesis
to reveal such information in order to enforce its rights under this Agreement
or if disclosure is required by law, regulation or judicial order. Any person or
entity conducting such audit or inspection will agree in writing with NeoGenesis
to treat all records reviewed in the course of the audit or inspection as the
Confidential Information of Aventis under terms and conditions no less
restrictive than the terms contained in Section 5.2. The results of each
inspection, if any, shall be binding on both parties. NeoGenesis shall pay for
such inspections, except that in the event there is any upward adjustment in
aggregate royalties payable for any year shown by such inspection of more than
five percent (5%) of the total amount paid during the period that is the subject
of the inspection, Aventis shall pay for such inspection.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

4.8 TAXES. If at any time, any jurisdiction within the Territory requires the
withholding of income taxes or other taxes imposed upon payments set forth in
this Section 4, Aventis shall make such withholding payments as required and
subtract such withholding payments from the payments to be made to NeoGenesis as
set forth in this Section 4, or if applicable, NeoGenesis will reimburse Aventis
or its designee(s) of the amount of such withholding payments that are not
subtracted from the payments made to NeoGenesis as set forth in this Section 4.
Aventis shall provide NeoGenesis with documentation of such withholding and
payment in a manner that is satisfactory for purposes of reporting to the U.S.
Internal Revenue Service. Any withholdings paid when due hereunder shall be for
the account of NeoGenesis. Withholding payments made by Aventis pursuant to this
Section 4.8 shall be made based upon financial information provided to Aventis
by NeoGenesis, and to the extent that such information is incorrect, NeoGenesis
shall be liable for any deficiency, and any fine, assessment or penalty imposed
by any taxing authority in the Territory for any deficiency in the amount of any
such withholding or the failure to make such withholding payment. If Aventis is
required to pay any such deficiency, or any fine, assessment or penalty for any
such deficiency, NeoGenesis shall promptly reimburse Aventis for such payments.
The parties will cooperate to minimize, to the extent legally permissible, the
tax liabilities related to this Agreement. Notwithstanding the foregoing, such
cooperation shall not cause any adverse tax consequences to be incurred by
either party which would not have been incurred under the provisions of this
Agreement, including this Section 4.8. No U.S. sales tax or similar taxes will
be due by Aventis on any of the contractual payments set forth in this Section
4.

4.9 INVOICES. All payments will be made thirty (30) days after receipt of an
invoice in the name of Aventis Pharma S.A and sent to the following address:

     Aventis Pharma S.A.
     Comptabilite Fournisseurs
     Tri 403
     20, avenue Raymond Aron
     F-92160 ANTONY

     The invoice should mention: "Dossier gere par N. Delbos"

5.  CONFIDENTIALITY

5.1 PUBLICITY. Except as is necessary to enforce their respective rights under
this Agreement, or to a party's legal or financial advisors, and except as
otherwise agreed to by the parties in writing, the parties shall: (a) keep the
material terms of this Agreement confidential; and (b) agree upon the text and
the exact timing of an initial public announcement relating to the transactions
contemplated by this Agreement as soon as practicable after the Effective Date
(such agreement not to be unreasonably withheld or delayed). Each party may
thereafter disclose to third parties the specific information contained in such
public announcement without the need for further approval by the other party.
Nothing in this Section 5.1 shall prohibit a party from making such disclosures
to the extent required under applicable federal or state securities laws or any
rule or regulation of any nationally recognized securities exchange. In such
event, however, the disclosing party shall use good faith efforts to notify and
consult with the other party prior to such disclosure and, where applicable,
shall diligently seek confidential treatment to the extent such treatment is
available under applicable securities laws.

5.2 CONFIDENTIALITY. (a) Confidential Information of each party will be used by
the other party solely for the purposes permitted by this Agreement. All
Confidential Information will be received and held in confidence by the
receiving party, subject to the provisions of this Agreement. Each party
acknowledges that it will not obtain any rights of any sort in or to the
Confidential Information of the other party as a result of such disclosure and
that any such rights must be the subject of separate written agreement(s).
Either party may only disclose the general nature, but not the specific
financial terms, of this Agreement without the prior consent of the other party;
PROVIDED that either party may provide a copy of this Agreement or disclose the
terms of this Agreement (i) to any finance provider in conjunction with a
financing transaction, if such finance provider agrees to keep this Agreement
confidential, (ii) to any legal or financial advisor of such party, or (iii) in
response to a subpoena or other validly issued administrative

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

or judicial process requesting disclosure of same; PROVIDED, the party that
receives such order or process provides prompt notice to the disclosing party
before making any disclosure and permits the disclosing party to oppose or
narrow such request for disclosure and supports any of disclosing party's
reasonable efforts to oppose such request (at disclosing party's expense) and
shall disclose the terms of this Agreement only in the event of a final judgment
or administrative order requiring such disclosure, and only to the extent
necessary to comply with such request.

     (b) Each party will restrict disclosure of the other party's Confidential
Information to those of its employees to whom it is necessary to disclose such
Confidential Information in connection with the purposes permitted under Section
5.2(a). Each party shall use reasonable efforts, including at least efforts
fully commensurate with those employed by the party for the protection of its
own Confidential Information, to protect the Confidential Information of the
other party.

     (c) Either disclosing party may at any time notify the receiving party that
such receiving party must return to the disclosing party the disclosing party's
Confidential Information. Each party hereby agrees to, within thirty (30) days
of such notification: (i) return all documents and tangible items it or its
employees or agents have received or created pursuant to this Agreement
pertaining, referring or relating to the other party's Confidential Information;
and (ii) return or certify (in a writing attested to by a duly authorized
officer of such party) destruction of all copies, summaries, modifications or
adaptations that such party or its employees or agents have made from the
materials provided by the disclosing party.

     (d) Nothing herein shall prevent a receiving party from disclosing all or
part of the Confidential Information as necessary pursuant to the lawful
requirement of a governmental agency or when disclosure is required by operation
of law; PROVIDED that prior to any such disclosure, the receiving party shall
use reasonable efforts to: (i) promptly notify the disclosing party in writing
of such requirement to disclose; and (ii) cooperate fully with the disclosing
party in protecting against any such disclosure or obtaining a protective order.

5.3 PUBLICATIONS. Each party recognizes that the publication of papers regarding
results of the Program, including oral presentations and abstracts, may be
beneficial to both parties provided such publications are subject to reasonable
controls to protect Confidential Information. In particular, it is the intent of
the parties to maintain the confidentiality of any Confidential Information
regarding the compounds included in any patent application until such patent
application has been published. Accordingly, each party shall have the right to
review and comment upon any paper proposed for publication by the other party
regarding results of the Program, including oral presentations and abstracts,
which utilizes data generated from the Program or includes Confidential
Information of the other party and neither party will make any publication or
disclosure regarding the results of the Program without the prior written
consent of the other party. Before any such paper is submitted for publication,
the party proposing publication shall deliver a complete copy to the other party
at least thirty (30) days prior to submitting the paper to a publisher. The
receiving party shall review any such paper and give its comments to the
publishing party within twenty (20) days of the delivery of such paper to the
receiving party. With respect to oral presentation materials, the parties shall
make reasonable efforts to expedite review of such materials, and shall return
such items as soon as practicable to the disclosing party with appropriate
comments, if any, but in no event later than twenty (20) days from the date of
delivery to the receiving party. The disclosing party shall comply with the
other party's request to delete references to such other party's Confidential
Information in any such paper and agrees to withhold publication of same for an
additional one hundred eighty (180) days (or longer if necessary) in order to
permit the parties to obtain patent protection, if either of the parties deem it
necessary, in accordance with the terms of this Agreement. If there is a dispute
regarding publications, such dispute shall be resolved by the Steering
Committee.

6.  REPRESENTATIONS AND WARRANTIES.

6.1 AUTHORIZATION; ENFORCEABILITY. Each of Aventis and NeoGenesis represent and
warrant to the other that: (a) it is a corporation or limited liability company,
as applicable, duly organized and validly existing under the laws of its
jurisdiction of organization and has all requisite power and authority to enter
into this Agreement; (b) it is duly authorized by all requisite action to
execute, deliver and perform this Agreement and to consummate the transactions
contemplated hereby, and that the same do not conflict or cause a default with
respect to such party's obligations

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

under any other agreement; (c) it has duly executed and delivered this
Agreement; and (d) (i) it is authorized to disclose any and all Confidential
Information made available to the other party pursuant to this Agreement; and
(ii) it shall not disclose to the other party any information that is
confidential or proprietary to itself or to a third party unless such
information is identified as Confidential Information.

6.2 NEOGENESIS PERFORMANCE. (a) NeoGenesis hereby represents and warrants to
Aventis that: (i) NeoGenesis shall use Commercially Reasonable Efforts to
perform the Program using qualified personnel and in a good and workmanlike
manner consistent with industry standards of companies that are comparable to
NeoGenesis performing similar activities under similar circumstances; and (ii)
as of the Effective Date, there is no agreement known to NeoGenesis to which it
is a party and by which it is bound that would conflict with or be breached by
NeoGenesis granting Aventis the license in Section 3.1.

     (b) NeoGenesis hereby represents and warrants to Aventis that it has not
sought, and will not seek, patent protection on any of the compounds that will
be screened in the conduct of the Program.

6.3 DISCLAIMER. (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2, NeITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NeoMorph Screening Library, the
NeoMorph Focused Libraries, QSCD, the Preliminary Compounds, the Primary Active
Compounds, the Selected Compounds, the LEAD Compounds, THE SCREENING TARGETS,
THE PRODUCTS, THE NeoGenesis intellectual property, THE Aventis intellectual
property, THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE NeoGenesis PATENT RIGHTS
OR THE Aventis PATENT RIGHTS, OR SUCH PARTy'S OBLIGATIONS UNDER THIS AGREEMENT.

     (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NeoGenesis AND Aventis
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.2-7.3.

7.  RISK ALLOCATION

7.1 LIMITATION OF LIABILITY. EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS
UNDER SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH
RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

7.2 THIRD PARTY CLAIMS. Subject to the provisions of Section 7.4, each of
NeoGenesis and Aventis (each, in such capacity an INDEMNIFYING PARTY) will
defend, indemnify and hold harmless the other party, its subsidiaries, parent
corporations, affiliates, officers, directors, partners, members, shareholders,
employees, agents, and their successors and assigns (each, in such capacity, an
INDEMNIFIED PARTY) from and against any claim, suit, demand, loss, damage,
expense (including reasonable attorneys' fees of Indemnified Party(ies) and
those that may be asserted by a third party) or liability including but not
limited to claims for death or personal injury (collectively, LOSSES) imposed
upon the Indemnified Party(s) by any third party arising from or related to: (a)
any material breach of the Indemnifying Party's representations and warranties
under this Agreement; or (b) any negligence or intentional misconduct by the
Indemnifying Party (or its employees, agents, representatives, Affiliates,
licensees, sublicensees or distributors) in performing its obligations under
this Agreement, including the performance of the Program or the R&D Program; or
(c) (with respect to Aventis as an Indemnifying Party) the labeling, packaging,
package insert, other materials or promotional claims with respect to any
Product or the development, testing, Manufacturing, Commercialization, use or
other disposition of any Product by Aventis or by an Affiliate, licensee,
sublicensee, distributor or agent of

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

Aventis. The foregoing indemnification action shall not apply in the event and
to the extent that such Losses arose as a result of any Indemnified Party's
negligence, intentional misconduct or breach of this Agreement.

7.3 INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless the Aventis Indemnified
Party(ies) from and against any Losses imposed upon them by any third party and
arising from or related to a third party claim that use of NeoGenesis
Intellectual Property or practice of the NeoGenesis Patent Rights by Aventis in
accordance with the terms of this Agreement violates or infringes the
intellectual property rights of any third party. NeoGenesis shall have no
liability or obligation to Aventis under this Section 7.3(a) in the event and to
the extent that the alleged infringement results from willful misconduct or
negligent acts or omissions of Aventis or its Affiliates, or its or their
respective employees, officers, directors or agents.

     (b) Subject to the provisions of Section 7.4, Aventis shall defend,
indemnify and hold harmless the NeoGenesis Indemnified Party(ies) from and
against any Losses imposed upon them by any third party and arising from or
related to a third party claim that use of the Aventis Intellectual Property or
the practice of the Aventis Patent Rights by NeoGenesis in accordance with the
terms of this Agreement violates or infringes the intellectual property rights
of any third party. Aventis shall have no obligation or liability to NeoGenesis
under this Section 7.3(b) in the event and to the extent that the alleged
infringement (i) is covered by Section 7.3(a) or (ii) results from willful
misconduct or negligent acts or omissions of NeoGenesis or its Affiliates, or
its or their respective employees, officers, directors or agents.

7.4 PROCEDURE. To receive the benefit of indemnification under Sections 7.2 or
7.3, the Indemnified Party must (a) promptly notify the Indemnifying Party of a
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations except where, and solely
to the extent that, such failure actually and materially prejudices the rights
of Indemnifying Party); (b) provide reasonable cooperation (at the Indemnifying
Party's expense); and (c) tender to the Indemnifying Party (and its insurer)
full authority to defend or settle the claim or suit; PROVIDED that no
settlement requiring any admission by the Indemnified Party or that imposes any
obligation on the Indemnified Party shall be made without the Indemnified
Party's consent. Neither party has any obligation to indemnify the other party
in connection with any settlement made without the Indemnifying Party's written
consent. The Indemnified Party has the right to participate at its own expense
in the claim or suit and in selecting counsel therefor. The Indemnified Party
shall cooperate with Indemnifying Party (and its insurer), as reasonably
requested, at Indemnifying Party's cost and expense.

8.   TERM AND TERMINATION

8.1 TERM. This Agreement shall take effect as the Effective Date and shall
remain in effect until the expiration date(s) specified in this Section 8.1,
unless sooner terminated in accordance with Section 8.2. The duration of the
Program will be thirty six (36) months from the Effective Date or such longer
period as is required for NeoGenesis to complete the Program in accordance with
Section 2.4 (the PROGRAM TERM). If the license under Section 3.1 is exercised,
such license will remain in effect on a country-by-country basis until the LATER
OF: (a) the expiration of the term of the last-to-expire of the patent rights
within the NeoGenesis Intellectual Property or Program Intellectual Property
owned by or licensed to NeoGenesis (including those NeoGenesis Patent Rights
assigned to Aventis pursuant to Section 3.2(d)) covering the applicable Lead
Compounds or the corresponding Product or (b) ten (10) years following the First
Commercial Sale of such Product.

8.2 TERMINATION. (a) NeoGenesis may terminate the Program with thirty (30) days'
notice to Aventis if Aventis fails to pay fees not contested in good faith due
under the Agreement or commits a material breach, unless the nonpayment or
breach is cured within the 30-day notice period. Aventis may terminate the
Program with thirty (30) days notice to NeoGenesis if NeoGenesis commits a
material breach unless the breach is cured within the thirty (30)-day notice
period. In addition, NeoGenesis may suspend work pursuant to the Program with
notice to Aventis if Aventis fails to pay NeoGenesis any amount due NeoGenesis
under this Agreement.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

     (b) Aventis may terminate the Program on the first anniversary of the
Effective Date based on Aventis' dissatisfaction with the results of the
Screening Program. Aventis may terminate the Hit Exploration Program at any time
with or without cause upon one hundred eighty (180) days notice.

     (c) Following completion of the Program, either party may terminate the
license, on a Product-by-Product basis, with sixty (60) days notice if the other
commits a material breach (including non-payment) unless the breach is cured
within the sixty (60)-day notice period.

     (d) Either party shall have the right to terminate this Agreement upon
thirty (30) days notice if a Force Majeure condition has prevented performance
by the other party for more than one hundred twenty (120) consecutive days. The
parties may also terminate this Agreement at any time upon mutual written
agreement of the parties.

     (e) Aventis shall have the right to terminate the license on a Lead
Compound-by-Lead Compound basis at any time with sixty (60) days notice.

8.3 EFFECT OF TERMINATION. (a) Upon termination (including expiration) of this
Agreement: (i) NeoGenesis will terminate all Program tasks (if any) then in
process in an orderly manner, as soon as practical and in accordance with a
schedule agreed to by Aventis and NeoGenesis; (ii) Aventis shall pay NeoGenesis
any monies due and owing NeoGenesis up to the time of termination, for services
actually performed (including all work-in process (if any) pursuant to the last
sentence of Paragraph 7 or Paragraph 8 of ATTACHMENT A), PROVIDED, such fee
shall not exceed the price specified in this Agreement and (iii) within thirty
(30) days following termination (including expiration) of this Agreement,
NeoGenesis shall deliver to Aventis a reasonably-detailed written report
describing the results of the Program services performed up to the date of such
termination.

     (b) Upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all documents and other tangible items it or its employees or
agents have received or created pertaining, referring or relating to the
Confidential Information of the other party.

     (c) The licenses granted by NeoGenesis under Section 3.1 shall survive any
expiration or termination of the Program or this Agreement with respect to any
Lead Compound or Product for which the applicable fees and milestone fees and
royalties have been paid (when due in accordance with the terms of this
Agreement) and Aventis shall continue to have the right to develop, have
developed, make, have made, use, distribute, offer for sale, import, export and
sell Lead Compounds and Products; PROVIDED that Aventis continues to pay
NeoGenesis the fees and royalties as required by Sections 4.1, 4.3 and 4.4 and
complies with Sections 4.5-4.8. The licenses granted under Section 3.1 shall not
survive termination or expiration with respect to Lead Compounds or Products for
which Aventis has not made payment in accordance with this Agreement and shall
immediately terminate with respect to any Lead Compound or Product for which the
applicable service fees and milestone fees are not timely paid (should such
payment become due after termination of this Agreement or for any Product for
which Aventis fails to pay NeoGenesis fees and royalties as required by Sections
4.1, 4.3 and 4.4 or fails to comply with Sections 4.5-4.8 subject to the
opportunity to cure described in Section 8.2(b). In the event the license
granted to Aventis under Section 3.1 terminates for any reason, each of Aventis'
sublicensees at such time shall continue to have the rights and license set
forth in their sublicense agreements, PROVIDED such sublicensee agrees in
writing that NeoGenesis is entitled to enforce all relevant provisions directly
against such sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination.
Aventis' liability for any charges, payments or expenses due to NeoGenesis that
accrued prior to the termination date shall not be extinguished by termination,
and such amounts (if not otherwise due on an earlier date) shall be immediately
due and payable on the termination date.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

8.4 SURVIVAL. Sections 1, 2.8, 3.2, 3.3 and 5-9 shall survive any termination or
expiration of this Agreement. Section 4 shall survive any termination of this
Agreement with respect to Products (including Products that are covered by
Section 3.2(d)) PROVIDED, that Section 4 shall not survive expiration of this
Agreement with respect to any Product in accordance with the last sentence of
Section 8.1.

9.  GENERAL PROVISIONS.

9.1 ISSUE RESOLUTION. The parties shall use their best efforts to resolve any
controversy or dispute that arises under or relates to this Agreement through
good faith discussions. The parties shall initiate such discussions using the
following procedure. Either party shall notify the other party of the nature of
the controversy or dispute, providing sufficient detail to permit the other
party to understand same (a DISPUTE NOTICE). The representatives of the parties
shall meet within 30 days after the date that the non-sending party receives the
Dispute Notice to attempt to reach an agreement about the nature of the dispute
and a resolution of the dispute. If they are unable to resolve the dispute
within 60 days after their meeting, and do not agree to extend the time period
for resolving the dispute, or if the terms and conditions of the resolution or
settlement of the dispute are breached, the parties are free to pursue any
remedy at law or in equity. Pending resolution of any dispute covered by this
Section 9.1, both parties will continue their performance under this Agreement
including, without limitation, the payment of all amounts due to the other party
that are not in dispute.

9.2 GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the State of New York to the exclusion of
any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Notwithstanding
the foregoing, the parties shall use United States (Federal) patent laws for
purposes of governing and construing Sections 3.2-3.4 of this Agreement. The
United Nations Convention on Contracts for the International Sale of Goods shall
not apply to the transactions contemplated by this Agreement.

9.3 AMENDMENT AND WAIVER. No provision of or right under this Agreement shall be
deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

9.4 INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between Aventis and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. NeoGenesis shall be solely responsible for compensating all its
personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes. Aventis shall not provide NeoGenesis
personnel with any benefits, including but not limited to compensation for
insurance premiums, paid sick leave or retirement benefits.

9.5 ASSIGNMENT. Neither party may assign this Agreement or any of its rights and
obligations under this Agreement without the prior written consent of the other
party; PROVIDED, that either party may assign this Agreement to (a) any Person
to which such party transfers all or substantially all of its assets or with
which such party is consolidated or merged; (b) any Person that owns a majority
of the voting stock of such party; (c) a single Person of which such party owns
a majority of the voting stock; or (d) an Affiliate of the assigning party;
PROVIDED, FURTHER, that in each instance the assignee expressly assumes all
obligations imposed on the assigning party by this Agreement in writing and the
other party is notified in advance of such assignment.

9.6 SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

9.7 NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
three (3) business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one
business day after it is deposited with such courier), or sent by telefax (such
notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) to the address set forth on
the signature page to this Agreement or to such other place as any party may
designate as to itself by written notice to the other party.

9.8 SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court or arbitrator to replace any provision hereof so held
invalid, illegal or unenforceable with a valid provision which is as similar as
possible in substance to the invalid, illegal or unenforceable provision.

9.9 CAPTIONS. Captions of the sections and subsections of this Agreement are for
reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the terms
and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and HEREUNDER
refer to this Agreement as a whole and not merely to a section or paragraph in
which such words appear, unless the context otherwise requires. The singular
shall include the plural, and each masculine, feminine and neuter reference
shall include and refer also to the others, unless the context otherwise
requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. In making proof of this Agreement, it shall not be
necessary to produce or account for more than one such counterpart.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation, other than a
payment obligation, created by this Agreement is caused by a Force Majeure
condition, that obligation shall be suspended during the continuance of the
Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

NeoGenesis PHARMACEUTICALS, INC.        Aventis PHARMA S.A.

Name:         Peter T. Lomedico         Name:        Emmanuel Canet
Title:        Vice President            Title:       Directeur General
              Strategic Alliances
Signature:    /s/ Peter T. Lomedico     Signature:   /s/ Emmanuel Canet

Date:         December 20, 2001         Date:        December 21, 2001

NOTICE ADDRESS:                         NOTICE ADDRESS:
NeoGenesis Pharmaceuticals, Inc.        Aventis Pharma S.A.
                                        attn. R. Fleer
840 Memorial Drive                      13, quai Jules Guesde B.P. 14  94403
                                        Vitry-sur-Seine
Cambridge, MA 02139                     Cedex, France
Phone:  617.868.1500                    Phone: 33.1.55.71.33.55
Fax:  617.868.1515                      Fax: 33.1.55.71.33.77

                                        With a copy to:
                                        Aventis Pharmaceuticals Inc.
                                        attn. Vice President, Legal Corporate
                                        Development
                                        Mail Stop: BWA-303H
                                        Route 202-206
                                        Bridgewater, NJ 08807-0800
                                        Phone: 908.231.3537
                                        Fax: 908.231.4480

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

                                  ATTACHMENT A
                                RESEARCH PROGRAM

The Program to be performed by NeoGenesis with respect to the Screening Targets
will screen [*] compounds contained in the NeoGenesis NeoMorph Screening Library
against each Screening Target using the protocol described below.

SCREENING PHASE

1. Aventis will provide NeoGenesis with at least [*] nmol. of each of the
purified functionally-active Screening Target proteins. NeoGenesis will perform
initial experiments on the Screening Targets to determine screening conditions
in NeoGenesis' ALIS protocols. NeoGenesis will establish SOPs for ALIS screening
based on the preceding experiments.

2. Using the SOPs, NeoGenesis will perform ALIS screening of at least [*] and up
to [*] NeoMorph compounds against each Screening Target, such number being
determined by the Steering Committee on a Screening Target-by-Screening Target
basis. The ALIS screening will be carried out under moderately stringent
conditions to identify compounds that bind to the Screening Target with binding
affinities better than [*] micromolar (Kd < [*]) (each a PRELIMINARY COMPOUND).
The Steering Committee will review the Kds of such Preliminary Compound(s) and
select those that warrant further work.

3. NeoGenesis will purify or synthesize up to [*] Preliminary Compounds per
Screening Target selected by the Steering Committee for further work and will
deliver to Aventis [*] of each of these "discrete" Preliminary Compounds to
Aventis; PROVIDED, that upon the determination of the Steering Committee that
more than [*] discrete Preliminary Compounds should be synthesized for any
Screening Target, NeoGenesis will synthesize such additional discrete
Preliminary Compounds as directed by the Steering Committee and Aventis shall
reimburse NeoGenesis for the costs to synthesize such additional discrete
Preliminary Compounds. Aventis will evaluate the activity of these discrete
Preliminary Compound(s) in biochemical or in vitro functional assay or
Aventis will transfer such assays to NeoGenesis for evaluation of such
discrete preliminary Compounds at NeoGenesis. The party responsible for
evaluating the activity of such discrete Preliminary Compound(s) will notify
the other party of any discrete Preliminary Compound which has demonstrated
activity in a Screening Target-based biochemical/functional assay with IC50
of less than [*] micromolar (IC50 < [*]) and will notify the other party of
the results of such assays, including any discrete Preliminary Compound(s)
which has demonstrated activity in the Screening Target-based
biochemical/functional assays with IC50 of less than [*] micromolar (IC50
< [*]) (each, a PRIMARY ACTIVE COMPOUND) within [*] after completion of such
assays and not later than [*] after receipt of the discrete Preliminary
Compounds or the Screening Target-based biochemical /functional assay, as
applicable.

4. If either Aventis or NeoGenesis identifies one or more Primary Active
Compounds pursuant to Paragraph 3, then NeoGenesis will prepare a report for all
Primary Active Compound(s) that details the chemical structures, binding
affinities and IC50 values for such Primary Active Compound(s). NeoGenesis will
deliver such report to Aventis when it notifies Aventis of such Primary Active
Compounds or, if Aventis has conducted the biochemical/functional assays, within
[*] of receipt of the results of such assays from Aventis.

5. Aventis will select up to [*] Primary Active Compounds per Screening
Target, for further study or optimization by NeoGenesis. NeoGenesis will
perform [*]cycles of optimization for the Primary Active Compounds identified
by Aventis. To perform such optimization, NeoGenesis will create NeoMorph
Focused Libraries based upon such Primary Active Compounds and will perform
high stringency-ALIS screening to improve Kd values to [*] micromolar or
better (Kd < [*]) and to develop a preliminary SAR. The results of
this additional ALIS screening will be summarized in a report (each, a FINAL
TARGET REPORT) and submitted to the Aventis Hit Evaluation Committee (HEC)
for consideration.

6. The HEC may select one or more compounds (each, a HIT COMPOUND) from the
optimized Primary Active Compounds prepared by NeoGenesis pursuant to Paragraph
5. In selecting Hit Compounds, the HEC will consider

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

in good faith whether these satisfy the following criteria: (a) IC50/dose
response confirmed on purified/ re-synthesized Primary Active Compound; (b)
functional activity confirmed on purified/ re-synthesized Primary Active
Compound; (c) potential for chemical optimization of such Primary Active
Compound; (d) whether such Primary Active Compound is likely to lead to
patentable compounds; (e) selectivity of such Primary Active Compound on project
specific secondary assays (screening tree); (f) activity of such Primary Active
Compound in functional assay; (g) solubility; (h) mode of action of such Primary
Active Compound (case by case basis); and (i) whether such Primary Active
Compound revealed some SAR in small series ([*] compounds).

HIT EXPLORATION PHASE

7. NeoGenesis will purify or synthesize discrete Hit Compounds and will provide
Aventis with [*] of each discrete Hit Compound(s) for evaluation by Aventis in
Screening Target-based biochemical or in vitro functional assays (or Aventis
will transfer such assays to NeoGenesis for evaluation of such Hit Compounds at
NeoGenesis) and, at the direction of the Steering Committee, evaluation in
anti-infective, cytotoxicity and any other additional assays as determined by
the Steering Committee. NeoGenesis will prepare a report of such evaluation
including structures, Kds, IC50 values and results of all assays and will
deliver the report to Aventis within [*] following the completion of such
evaluation. Any additional quantities of Hit Compounds will be furnished to
Aventis at cost, which shall be based on the FTE rate.

8. Aventis will select a series of Hit Compounds for further optimization (each,
a SELECTED SERIES). NeoGenesis will perform additional optimization and all
necessary assays as directed by the Steering Committee to optimize the Selected
Series compounds to meet the Lead Compound criteria specified in clauses (a)-(h)
of the definition of Lead Compound(s). All such work will be carried out on FTE
basis and Aventis will provide funding for such work as provided in Section 4.2.
The decision whether any of the optimized Hit Compounds should be nominated as
Lead Compounds will be based on a detailed report (each, a CANDIDATE LEAD
COMPOUND REPORT) and a written recommendation of the Steering Committee. The
final decision on a Lead Compound nomination will be taken by the Aventis
Scientific Review Committee (SRC) in accordance with Section 2.8.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

WORK FLOWCHART

                          [GRAPHICS OF WORK FLOWCHART]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

                                  ATTACHMENT B
                          PROGRAM INTELLECTUAL PROPERTY
                          [TO BE SUPPLIED AS DEVELOPED]

                                  ATTACHMENT C
                                SCREENING TARGETS
                           [TO BE SUPPLIED BY AVENTIS]

                                  ATTACHMENT D
                        NEOGENESIS INTELLECTUAL PROPERTY
                  [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

                            NEOGENESIS PATENT RIGHTS
                  [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27<Page>

                                                                    Exhibit 10.8

                             CONFIDENTIAL TREATMENT

                                    AGREEMENT
This Agreement (AGREEMENT) is entered into as of June 18, 2001 (EFFECTIVE DATE)
between NeoGenesis, Inc., a Delaware corporation (NEOGENESIS) and Oxford
GlycoSciences (UK) Limited (OGS), a company incorporated under the laws of
England and Wales, and sets forth the terms and conditions that will apply to
the provision by NeoGenesis to OGS of certain screening and analysis services.

                                   BACKGROUND

OGS is interested in identifying potential pharmaceutical products for treatment
of certain human diseases and wishes to identify compounds that exhibit a high
degree of chemical binding and functional activity to specific protein targets.
NeoGenesis has certain technology and know-how, including screening processes of
libraries of mass-encoded small molecule compounds, relating to the
identification, discovery, validation and optimization of novel compounds which
may be useful for development of novel therapeutics employing targets implicated
in a disease process. The parties wish to pursue a collaborative screening
process to identify compounds exhibiting a high degree of chemical binding
activity to targets designated by OGS from among the NeoGenesis libraries of
mass-encoded small molecule compounds and which have activity in bioassays or
functional assays. The terms and conditions set forth below shall govern the
performance of such collaborative effort.

1.  DEFINITIONS.

1.1 DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meanings set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition, CONTROL means, with respect to any
Person, the direct or indirect ownership of more than fifty percent (50%) of the
voting or income interest in such Person or the possession otherwise, directly
or indirectly, of the power to direct the management or policies of such Person.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against target protein.

     APPLICABLE LAWS means all laws, statutes, regulations and ordinances of any
Regulatory Authority, including without limitation the FD&C Act with regard to
the FDA.

     CATEGORY "A" PUBLIC DOMAIN TARGET means a Public Domain Target that OGS has
identified and linked to a disease through use of its proteomic research
activities, including without limitation its proprietary 2d gel electrophoresis
technology at the time OGS discloses such Public Domain Target.

     CATEGORY "B" PUBLIC DOMAIN TARGET means a Public Domain Target that OGS has
identified other than through use of its proteomic research activities at the
time OGS discloses such Public Domain Target.

     CHEMOTYPE means a family or group of related Preliminary Compounds (as
defined in ATTACHMENT A).

     CIP means "Carriage and Insurance Paid", as that expression is defined in
INCOTERMS 2000, ICC Publishing S.A.

     COMMERCIALLY REASONABLE EFFORTS means, with respect to (i) any objective by
any party, reasonable, diligent, good faith efforts to accomplish such objective
as such party would normally use to accomplish a similar objective under similar
circumstances; and (ii) with respect to any objective relating to the
development or Commercialization of any Licensed Product by any party efforts
and resources normally used by such party with respect to a product owned by
such party or to which such party has similar rights which is of similar market
potential at a similar stage in the development or life of such product, taking
into account issues of safety, efficacy, product profile, the cost to develop,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved and the likelihood of regulatory approval,
profitability of the product and all other relevant commercial factors.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

     COMMERCIALIZATION means any and all activities of using, importing,
exporting, keeping (whether for disposal or otherwise), marketing, promoting,
distributing, offering for sale and selling a Licensed Product. When used as a
verb, COMMERCIALIZE means to engage in Commercialization.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to any and all OGS Proprietary
Targets, any and all OGS Know-How and any and all NeoGenesis Know-How) disclosed
to the other party pursuant to this Agreement in written or other tangible
medium and marked as confidential, or if disclosed orally or displayed,
confirmed in writing within thirty (30) days of disclosure, except any portion
thereof which: (i) is known to the receiving party, as evidenced by the
receiving party's written records, before receipt thereof under this Agreement;
(ii) is disclosed to the receiving party by a third person who is under no
obligation of confidentiality to the disclosing party hereunder with respect to
such information and who otherwise has a right to make such disclosure; (iii) is
or becomes generally known in the trade through no fault of the receiving party;
or (iv) is independently developed by the receiving party, as evidenced by the
receiving party's written records, without access to such information.

     CONTROL OR CONTROLLED means with respect to any (a) item of information,
including, without limitation, OGS Know-How and NeoGenesis Know-How, or (b)
intellectual property right, the possession of the right (whether directly or
indirectly and whether by ownership, license or otherwise, other than pursuant
to this Agreement) by a party or an Affiliate thereof to grant to the other
party access or a license as provided herein under such item or right without
violating the terms of any agreement or other arrangements, between such party
or its Affiliate and any third party, existing before or after the Effective
Date.

     EXCLUDED TARGET means a protein target which NeoGenesis has committed to a
Person (other than OGS) prior to such protein target being submitted by OGS to
NeoGenesis pursuant to this Agreement. The designation of a target as an
Excluded Target shall be made using the procedure described in Section 2.1(c).

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938, as amended.

     FIELD means the diagnosis or treatment of any disease in humans.

     FIRST COMMERCIAL SALE means, with regard to a Licensed Product, any
transfer for value in an arms-length transaction to an independent third party
distributor, agent or end user in a country within the Territory after obtaining
all necessary Regulatory Approvals as may be necessary for such transfer in such
country.

     FORCE MAJEURE means any event beyond the reasonable control of the parties,
including, without limitation, power failure, fire, flood, riots or strikes
(with the exception of riots or strikes involving a party's own workforce),
epidemics, war (declared or undeclared and including the continuance, expansion
or new outbreak of any war or conflict now in existence), embargoes and
governmental actions or decrees.

     FTE means the equivalent of a full time (12) months (including normal
vacations, sick days and holidays) work of a person, carried out by one or more
employees or agents of NeoGenesis, who devotes a portion of his or her time to
performing activities in connection with the conduct of the Program, such amount
per FTE not to exceed [*].

     IND means an investigational new drug application, as defined in the FD&C
Act and applicable regulations thereunder, or any equivalent document, filed
with the FDA and necessary for beginning clinical trials of any Licensed Product
in humans or any application or other documentation filed with any Regulatory
Authority of a country other than the United States prior to beginning clinical
trials of any Licensed Product in humans in that country.

     LICENSED PRODUCT(S) means any product: (a) which includes a Designated
Compound or any derivatives, improvements and components thereof; and (b) the
development, manufacture, use, or sale of which, absent the

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

license granted under this Agreement, would infringe the NeoGenesis Know-How or
NeoGenesis Patent Rights or which makes use of any Program Intellectual Property
that is jointly owned by the parties.

     MAJOR COUNTRY mean the United States, the United Kingdom, France, Germany,
Italy or Japan, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Licensed Product to be developed and/or Commercialized under this Agreement.
When used as a verb, MANUFACTURE means to engage in Manufacturing.

     NDA means a new drug application as defined in the FD&C Act and applicable
regulations thereunder, and the non-U.S. equivalent thereof.

     NEOGENESIS KNOW-HOW means all proprietary technical information, data and
know-how, including but not limited to all Program Intellectual Property
described in clause (a) of the definition of Program Intellectual Property,
relating to: (a) the NeoMorph Screening Library, (b) the NeoMorph Focused
Libraries, (c) ALIS and QSCD, (d) the Preliminary Compounds, (e) the Primary
Active Compounds, (d) the Selected Compounds, together with, where applicable,
any analogs, derivatives, fragments, sub-cellular constituents or expression
products thereof and (e) any other tangible materials provided by NeoGenesis to
OGS for use in the conduct of the Program, which (i) is Controlled by
NeoGenesis, (ii) primarily relates to a Designated Compound or Licensed
Products, whether or not patentable, and (iii) is listed in ATTACHMENT D, as
ATTACHMENT D is amended from time to time in accordance with Section 2.6 or
Section 3.3. The term NeoGenesis Know-How, HOWEVER, does not include (1) any OGS
Know-How, (2) any know-how, processes, information and data which is, as of the
Effective Date or later becomes, generally available to the public or (3) any
general manufacturing or other know-how not specific to the Designated Compound
or Licensed Products.

     NEOGENESIS PATENT RIGHTS means (a) those patents and patent applications
listed in ATTACHMENT D, as ATTACHMENT D is amended from time to time in
accordance with Section 2.6(b) or Section 3.3, which are Controlled by
NeoGenesis and are existing as of the Effective Date or filed or issued during
the term of this Agreement; and (b) any and all substitutions, divisionals,
continuations, continuations-in-part, reissues, renewals, registrations,
confirmations, re-examinations, extensions, supplementary protection
certificates and foreign or international equivalents or counterparts thereof.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
derived from Active Compounds identified by OGS in bioassays or functional
assays

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising at least 10,000,000 different
compounds.

     NET SALES means the aggregate amounts invoiced for sales or transfers for
value of Licensed Products by OGS, its Affiliates or any of its sublicensee to
an independent third party distributor, agent or end user in the Territory
(other than sales of Licensed Products at cost by OGS, its Affiliates or
sublicensees to a third party for use in a clinical study prior to Regulatory
Approval of such Licensed Product) LESS deductions selected as appropriate from:
(a) credits, refunds, allowances and price adjustments separately and actually
credited to customers for defective, spoiled, damaged, outdated, and returned
Licensed Products, (b) offered and taken trade, quantity and cash discounts and
rebates to customers in amounts customary to the trade and as required to do
business in the country in which they are made and reasonable and customary
commissions on sales of Licensed Product actually allowed to independent third
party "buyer side" intermediaries, (c) sales, excise, value added, turnover,
use, and other like taxes, and customs duties, paid, absorbed or allowed
excluding net income tax, including, without limitation, payments required by
law to be made to governmental authorities, pursuant to any product liability or
personal injury

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

compensation schemes in each case to the extent that the same are not capable of
being recovered or reimbursed; (d) reasonable standard costs for filling and
packaging of Licensed Product to include the standard costs for syringes or
other administration devices to the extent used, (e) any bad debts which are in
fact unrecoverable, and (f) outbound packing, transportation, insurance and
handling charges separately billed to the customer or prepaid. Net Sales shall
not include revenue received by OGS (or any of its Affiliates) from transactions
with an Affiliate, where the Licensed Product in question will be resold to an
independent third-party distributor, agent or end user by the Affiliate where
such revenue received by the Affiliate from such resale is included in Net Sales
in accordance with Section 4.3. Revenue received by OGS (or any of its
Affiliates) from transactions with an Affiliate, where the Licensed Product in
question is used by the Affiliate solely for such Affiliate's internal purposes
shall also be included in Net Sales at a price equal to the fair market value of
such transfer(s).

     OGS KNOW-HOW means all proprietary technical and clinical information, data
and know-how, including but not limited to all Program Intellectual Property
described in clause (c) of the definition of Program Intellectual Property,
relating to: (a) the Targets, (b) the Designated Compounds, together with, where
applicable, any analogs, derivatives, fragments, sub-cellular constituents or
expression products thereof, or (c) the Licensed Products, whether or not
patentable, Controlled by OGS or its Affiliates as of the Effective Date or
during the term of this Agreement. OGS Know-How includes, without limitation,
all processes, formulas, discoveries and inventions whether relating to
biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical safety, quality control and clinical data, including, without
limitation, clinical study data. OGS Know-How also includes relevant medical
information relating to the Licensed Products (such as customer questions,
responses thereto and adverse drug event) history in the possession of OGS, its
Affiliates or sublicensees. The term OGS Know-How, however, does not include the
NeoGenesis Know-How or any know-how, processes, information and data which is,
as of the Effective Date or later becomes, generally available to the public.

     OGS PATENT RIGHTS means (a) those patents and patent applications (other
than patent applications and patents included within the NeoGenesis Patent
Rights) Controlled by OGS at any time during the term of this Agreement which
relate to or otherwise would be infringed by the manufacture, use, importation
or sale of any Designated Compound or Licensed Product and (b) any and all
substitutions, divisionals, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions,
supplementary protection certificates and foreign or international equivalents
or counterparts thereof.

     OGS PROPRIETARY TARGET means a protein target for which (a) a patent has
issued to OGS claiming such protein target (including patents that have been
assigned to or licensed by OGS) and which has not expired, lapsed, or been held
invalid, unpatentable or unenforceable by a final decision, which is unappealed
or unappealable, of a court of competent jurisdiction or of an administrative
agency having authority over patents; or (b) a patent application has been filed
which patent application has not been the subject of a rejection notice from
which an appeal cannot be taken or in respect of which the applicable period of
appeal has expired (including patent applications that have been assigned to or
licensed by OGS).

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization.

     PROGRAM means the screening program described in ATTACHMENT A as the same
may be amended during the term of this Agreement by mutual agreement of the
parties acting through the Steering Committee (as defined below). The Program
will be directed toward the discovery and development of Primary Active
Compounds and Selected Compounds for the Targets, the re-synthesis and
confirmation of such Compounds and the supply of purified quantities of such
compounds to OGS in accordance with the pre-defined amounts and pre-defined
purities set out in ATTACHMENT A.

     PROGRAM INTELLECTUAL PROPERTY means individually and collectively all
discoveries, inventions, know-how, techniques, methodologies, modifications,
improvements, works of authorship, designs and data (whether or not protectable
under patent, copyright, trade secrecy or similar laws) that are conceived,
created, discovered, developed, or reduced to practice or tangible medium of
expression (a) solely by one or more employees or consultants of NeoGenesis at
any time in the course of the Program; (b) jointly by one or more employees or
consultants of

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

NeoGenesis and one or more employees or consultants of OGS at any time in the
course of the Program; or (c) solely by one or more employees or consultants of
OGS at any time in the course of the Program. Program Intellectual Property is
listed in ATTACHMENT B, which shall be amended from time-to-time to include new
Program Intellectual Property, in accordance with Section 3.3.

     PUBLIC DOMAIN TARGET means a protein target which has been implicated in a
human disease in published scientific literature prior to its submission by OGS
to NeoGenesis as a Target. Where the context so requires, references to Public
Domain Targets shall include Category "A" Public Domain Targets and/or Category
"B" Public Domain Targets, as appropriate.

     QSCD means Quantisized Surface Complimentary Diversity, a model proprietary
to NeoGenesis, in terms of which discrete chemical compliments to the surfaces
of a Target are defined.

     R&D PROGRAM means on a Designated Compound-by-Designated Compound and
country-by-country basis the activities necessary or desirable to be undertaken
in connection with the research and development of such Designated Compound
prior to obtaining Regulatory Approval for a Licensed Product in such country
(regardless of the country in which such activities are conducted).

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, marketing, promotion, pricing and sale of the Licensed
Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA.

     SUCCESS CRITERIA means the success criteria defined by the Steering
Committee with respect to Selected Compounds that have a certain desired degree
of chemical binding activity and activity in Target-based functional assays.

     TARGET means a specific protein target(s) selected by OGS for which
NeoGenesis will perform the Program. The Target(s) are identified in ATTACHMENT
C. For the avoidance of doubt, a Target may be an OGS Proprietary Target or a
Public Domain Target, and in either case, such a Target may be validated or
unvalidated.

     TERRITORY means all the countries of the world.

1.2 OTHER DEFINED TERMS. The following terms shall have the meanings set forth
in the section appearing opposite such term:

<Table>
         <S>                                         <C>
         AGREEMENT                                   Recitals
         BANKRUPTCY CODE                             Section 3.1
         CLAIM NOTICE                                Section 6.6
         COMPOUNDS                                   ATTACHMENT A
         DESIGNATED COMPOUND                         Section 2.6
         EFFECTIVE DATE                              Recitals
         ICC                                         Section 9.1
         INDEMNIFYING PARTY                          Section 7.4
         FINAL TARGET REPORT                         ATTACHMENT A
         LICENSED TECHNOLOGY                         Section 3.1
         LOSSES                                      Section 7.2
         NEOGENESIS                                  Recitals
         NEOGENESIS INDEMNIFIED PARTY                Section 7.3
         OGS                                         Recitals
         OGS INDEMNIFIED PARTY                       Section 7.2
         PHASE I CLINICAL TRIALS                     Section 4.3
         PHASE II CLINICAL TRIALS                    Section 4.3
         PHASE III CLINICAL TRIALS                   Section 4.3

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

         POTENTIALLY EXCLUDED TARGET                 Section 2.1(c)
         PRELIMINARY COMPOUND                        ATTACHMENT A
         PRIMARY ACTIVE COMPOUNDS                    ATTACHMENT A
         PROGRAM COMMENCEMENT DATE                   Section 2.1(a)
         PROGRAM TERM                                Section 8.1
         REJECTED RIGHTS                             Section 3.3(b)
         ROYALTY TERM                                Section 4.5
         SCREENING PERIOD                            Section 2.2
         SELECTED COMPOUND(S)                        ATTACHMENT A
         STEERING COMMITTEE                          Section 2.5
</Table>

2.  SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION

2.1 DISCLOSURE OF TARGET PROTEINS. (a) During the Program Term, OGS shall from
time to time disclose Targets to NeoGenesis in writing marked for the attention
of Satish Jindal. The parties intend that Target disclosure will be made at an
average rate of [*] Targets per quarter and up to a maximum of [*] Targets per
year. To the extent that any shortfall arises between the proposed number of
Targets to be disclosed and the actual number of Targets disclosed by OGS during
any [*] period of the Program Term, OGS shall have the right but not the
obligation to provide Targets to make up such shortfall during the remaining
term of this Agreement; PROVIDED, that (i) NeoGenesis shall not be required to
initiate screening pursuant to Section 2.2 of more than [*] Targets in any [*]
period of the Program Term and (ii) OGS shall complete all Target disclosure not
later than the beginning of [*] following the commencement of the Program by
NeoGenesis with respect to the first Target, as noticed to OGS by NeoGenesis in
accordance with Section 9.7 (PROGRAM COMMENCEMENT DATE). For the avoidance of
doubt, it is agreed by the parties that it shall not be a breach of this
Agreement should OGS deliver less than [*] Targets in any year of this
Agreement, but that OGS shall not be permitted to propose Targets after the
beginning of the [*] following the Program Commencement Date except to the
extent that a Target submitted at the beginning of the [*] following the Program
Commencement Date is excluded by NeoGenesis pursuant to the terms of Section
2.1(c); PROVIDED FURTHER, that OGS provides an alternative Target for such
Excluded Target within [*] following the date NeoGenesis notifies OGS that such
Target has been excluded.

     (b) OGS will make the initial disclosure of proposed Targets within [*] of
the Effective Date such disclosure to include not less than [*] proposed
Targets.

     (c) Within [*] of each disclosure of a proposed Target by OGS, NeoGenesis
shall notify OGS as to whether such Target is an Excluded Target. If NeoGenesis
does not serve such notice with the specified period, such Target shall not be
deemed to be an Excluded Target. NeoGenesis may deem a Target as an Excluded
Target if such Target: (i) is the subject of an internal NeoGenesis screening
program; (ii) is already the subject of a contract between NeoGenesis and a
third party; or (iii) has already been disclosed to NeoGenesis by a third party
with the intention that such Target become the subject of a contract between
NeoGenesis and such third party (a POTENTIALLY EXCLUDED TARGET); PROVIDED, that
with respect to Potentially Excluded Targets pursuant to Section 2.1(c)(iii),
such Targets shall only become Excluded Targets if NeoGenesis and the applicable
third party enter into an agreement for such Potentially Excluded Target within
[*] following the date on which NeoGenesis identifies such Target as a
Potentially Excluded Target. NeoGenesis undertakes to promptly notify OGS in
writing: (A) if a contract is signed within the [*] period; or (B) upon the
expiry of the said [*] period if a contract has not been signed; with regard to
any such Potentially Excluded Target and to the extent that no such contract has
been entered into, such Potentially Excluded Target shall automatically be
deemed a Target unless OGS otherwise notifies NeoGenesis within [*] of receipt
of said notice.

     (d) OGS Targets may be either Public Domain Targets or OGS Proprietary
Targets; PROVIDED, that the aggregate number of Category "B" Public Domain
Targets that NeoGenesis shall be obligated to accept pursuant to this Agreement
shall not exceed [*] during each 12-month period of the Program Term.

2.1A DELIVERY OF TARGET PROTEINS. OGS shall deliver Targets that have been
accepted by NeoGenesis to NeoGenesis within [*] following acceptance by
NeoGenesis in accordance with Section 2.1. OGS shall provide such Targets in the
quantities and formats specified in ATTACHMENT A. OGS shall also provide
NeoGenesis at the time of

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

delivery with a written description of the concentration and volume of the
Target in order to assist NeoGenesis in performing the screening activities
contemplated by the Program. OGS shall deliver the Targets CIP to NeoGenesis's
Cambridge facility. The Targets will be packed and shipped by OGS in accordance
with good commercial practice, and OGS shall bear the risk of loss of each
Target until it is delivered to NeoGenesis.

2.2 SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the
NeoMorph Library for activity with respect to each Target for purposes of
identifying potentially useful chemical compounds for further evaluation and
development. Screening will be performed pursuant to the screening protocol for
the Program set forth in ATTACHMENT A. With respect to each Target delivered by
OGS, NeoGenesis shall initiate its screening obligations as more particularly
set out in the Program within [*] following the date of receipt of such Target
and complete such screening obligations within [*] following the date it
commences its screening obligations with respect to such Target, unless the
parties agree in writing to extend the period for performance and except as
otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD).

     (b) Notwithstanding any provision of this Agreement to the contrary, it is
understood and agreed that while NeoGenesis will attempt to complete the Program
within thirty six (36) months following the Effective Date, in the event and to
the extent that NeoGenesis has not completed the Program with respect to any
Target(s) disclosed by OGS within thirty three (33) months following the Program
Commencement Date (or thereafter with respect to Targets that are excluded by
NeoGenesis as contemplated by Section 2.1(a)) NeoGenesis will continue to
perform the Program during the period following the expiration of thirty six
(36) months following the Effective Date until NeoGenesis completes the Program
for each Target submitted in accordance with Section 2.1(a) and NeoGenesis shall
not bill OGS any additional fees with respect to the work required to complete
the Program with respect to such Targets following the expiration of such thirty
six (36) month period; PROVIDED, OGS has paid all fees required under Section
4.2 and PROVIDED FURTHER that NeoGenesis may bill OGS for any additional fees
due NeoGenesis in respect of "additional" work as contemplated by ATTACHMENT A
(Items 6-7).

2.3 GRANT OF RESEARCH LICENSE. OGS hereby grants NeoGenesis a nonexclusive,
nontransferable, royalty-free license to use OGS Know-How and OGS Patent Rights
solely for the purposes of conducting the Program and performing NeoGenesis's
obligations to OGS under the Program. NeoGenesis will not use OGS Know-How or
OGS Patent Rights for any other purpose, without OGS's prior written permission.
NeoGenesis shall not (a) grant, or attempt to grant, a sub-license to use OGS
Know-How or OGS Patent Rights to any Person without the express written consent
of OGS, (b) perform any tests on any of the Targets that are outside the scope
of the Program, or (c) modify the Targets supplied by OGS, including, without
limitation, the making of any derivatives, analogs or components thereof. In the
event that NeoGenesis does not consume all quantities of the Targets supplied by
OGS in performance of the Program, NeoGenesis will, upon completion of the
Program promptly, return to OGS any quantities of such Target(s) and any
derivatives, analogs or components thereof or destroy said quantities, at OGS's
option.

2.3A EXCLUSIVITY. (a) NeoGenesis agrees and undertakes that it will not conduct
screening services for any third Person in respect of any Targets during the
period from the date they are declared by OGS until:

     (i) [*] following the date OGS designates a Designated Compound for such
     Target (or the date [*] following the date NeoGenesis delivers Selected
     Compounds for such Target if OGS fails to designate a designated Compound
     within such [*] period) for OGS Proprietary Targets;

     (ii) [*] following the date OGS delivers such Target for Category "A"
     Public Domain Targets ; and

     (iii) the date OGS designates a Designated Compound for such Target (or the
     date [*] following the date NeoGenesis delivers Selected Compounds for such
     Target if OGS fails to designate a designated Compound within such [*]
     period) for Category "B" Public Domain Targets.

     (b) Upon the expiration of the applicable exclusivity period as specified
under Section 2.3A(a): (i) NeoGenesis may conduct screening services for any
third Person in respect of any Targets; PROVIDED, that until the [*] anniversary
of the expiration date of the applicable exclusivity period as specified under
Section 2.3A(a) such services are performed at the request of such third party
and not as a result of any solicitation by NeoGenesis regarding such

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

Target; and (ii) NeoGenesis shall not conduct any screening services for its
internal development programs until the third anniversary of the applicable
exclusivity period as specified under Section 2.3A(a).

     (c) It is understood and acknowledged by NeoGenesis that the restriction
imposed by this Section 2.3A operates independently of any OGS Patent Right(s)
that OGS may hold in respect of any OGS Proprietary Target.

2.4 SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Program to enable it
to furnish complete and accurate information to OGS regarding the Program
activities and results, including all Preliminary Compounds, Active Compounds
and NeoMorph Focused Libraries identified in the Program and all Program
Intellectual Property developed during the Program. All such written records of
NeoGenesis shall be open to inspection by OGS during normal business hours upon
reasonable prior written notice.

     (b) NeoGenesis shall provide OGS with reasonably-detailed written reports
describing the results of the research performed pursuant to the Program
including all Preliminary Compounds, Active Compounds and NeoMorph Focused
Libraries identified in the Program. Such reports shall be delivered to OGS at
least monthly during the Program. NeoGenesis will deliver a Final Target Report
(as defined in ATTACHMENT A) with respect to the Program work performed on each
Target including a description of all the Preliminary Compounds, Primary Active
Compounds and NeoMorph Sublibraries identified during the Program with respect
to such Target.

2.5 STEERING COMMITTEE. (a) A Steering Committee (STEERING COMMITTEE) shall be
responsible for the day-to-day management of the Program. The Steering Committee
shall consist of four members, two members to be appointed by each of NeoGenesis
and OGS. Each party may with notice to the other substitute any of its members
serving on the Steering Committee. The initial OGS members shall be Professor
Raj Parekh and Dr David Scopes and the initial NeoGenesis members shall be
Satish Jindal and Huw Nash. Each member of the Steering Committee will have one
vote and all decisions of the Steering Committee will be by unanimous agreement.

     (b) The Steering Committee shall be responsible for the management and
conduct of the Program and shall in particular: (i) consider, review and amend
the Program from time to time in such manner as may be appropriate; (ii) monitor
progress of the Program; (iii) report regularly to the management of both
parties upon the progress of the Program; and (iv) be the initial medium for
transfer of information between the parties.

     (c) The Steering Committee shall hold meetings as mutually agreed by the
parties (but in no event less than quarterly during the Research Term) to review
the Program. The first meeting of the Steering Committee shall be held within
forty-five (45) days of the Effective Date and shall be held in Cambridge, MA.
Thereafter, meetings may be held by telephone or video conference if requested
by either party in writing to the other, PROVIDED THAT the parties shall meet in
person at least two (2) times a year during the Research Term. The party hosting
the meeting shall circulate an agenda at least five (5) business days prior to a
meeting. Minutes of all meetings setting forth decisions of the Steering
Committee relative to the Screening Process shall be prepared by the host party
and circulated to both parties within fifteen (15) days after each meeting, but
minutes shall not become official until approved by both parties (which approval
the parties shall use reasonable efforts to give within thirty (30) days of
receipt of such minutes).

     (d) The quorum for Steering Committee meetings shall be two, provided that
at least one member from each of NeoGenesis and OGS is present. Disagreements
among the Steering Committee regarding the Program will be resolved via
good-faith discussions; PROVIDED, that in the event of a disagreement that
cannot be resolved within thirty (30) days after the date on which the
disagreement arose, the matter shall be referred to between OGS's Chief
Executive Officer and NeoGenesis's Chief Executive Officer or their respective
designees. Thereafter, if any such disagreement is not resolved within sixty
(60) days, then OGS shall have the right to make the final decision.

2.6 DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Selected
Compounds for each Target by NeoGenesis in accordance with Section 2.4 and
ATTACHMENT A (or the delivery of the corresponding notice regarding Primary
Compound Activity by OGS in accordance with ATTACHMENT A), OGS shall notify
NeoGenesis whether it will classify any Selected Compounds (or any derivative
compound(s) of such Selected Compounds) as the basis for optimisation so as to
yield a candidate for drug development based on OGS's good faith evaluation of

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

the satisfaction of the Success Criteria by such Selected Compound (or any
derivative compound(s) of such Selected Compounds) (each, a DESIGNATED
COMPOUND). If OGS does not identify any Designated Compound(s) within such
period, the license granted OGS shall terminate and be of no further force or
effect with respect to the applicable Target, and no further payment from OGS
shall be due with respect to such Target.

     (b) Within thirty (30) days of the Effective Date, NeoGenesis shall update
ATTACHMENT D. Thereafter, within thirty (30) days following receipt of
notification from OGS identifying Designated Compounds, NeoGenesis shall amend
ATTACHMENT D to identify any applicable NeoGenesis Patent Rights not previously
identified to OGS. For the avoidance of doubt, to the extent that ATTACHMENT D
is not updated to include any NeoGenesis Patent Rights that OGS requires to
exercise its license under Section 3.1, NeoGenesis agrees that it shall not have
any action against OGS in relation thereto and shall automatically amend
ATTACHMENT D to include such NeoGenesis Patent Rights.

2.7 REGULATORY MATTERS. OGS shall use Commercially Reasonable Efforts to file
Regulatory Approval applications in the Major Countries (excluding Japan).
Simultaneously with the submission of each such regulatory filing, OGS shall
notify NeoGenesis, in writing, that such regulatory filing has been made and
upon NeoGenesis's request, provide NeoGenesis with a copy thereof. OGS shall be
solely responsible for reporting all adverse events associated with any Licensed
Product to the appropriate Regulatory Authorities in accordance with Applicable
Laws.

2.8 MARKETING AND SALE. OGS, at its sole expense, shall be solely responsible
for the Commercialization of Licensed Products in the Territory and shall use
its Commercially Reasonable Efforts to Commercialize each Licensed Product in
each of the Major Countries (excluding Japan). OGS shall be solely responsible
for establishing the price of each Licensed Product sold by or on behalf of it
pursuant to this Agreement.

2.9 THIRD PARTY LICENSES. OGS shall be solely responsible for (a) obtaining any
and all licenses from third parties necessary or desirable to perform the R&D
Program and/or to Commercialize any Licensed Product and (b) save as otherwise
provided in Section 4.4A, any and all consideration payable with respect to such
licenses.

2.10 COMPLIANCE WITH LAW. OGS shall conduct the R&D Program and its
Manufacturing operations in compliance with all Applicable Laws , and in
compliance with all applicable provisions of this Agreement (to the extent that
such provisions do not contravene such Applicable Laws). OGS shall obtain all
necessary Regulatory Approvals, registrations and permits pertaining to
activities contemplated by this Agreement as required by all Applicable Laws.

2.11 PERIODIC REVIEW. OGS and NeoGenesis shall periodically meet, at such times
and places as are mutually agreed upon, for OGS to provide NeoGenesis with an
update on the status of the progress of OGS's Commercialization of each Licensed
Product, PROVIDED, HOWEVER, that such meetings shall occur no more than once per
calendar year unless the parties agree, in writing, to meet more often. OGS and
NeoGenesis shall each be responsible for its own expenses incurred in connection
with attending such meetings.

3.  LICENSE; PROPRIETARY RIGHTS

3.1 GRANT OF LICENSE. (a) Subject to the terms and conditions of this Agreement,
including the payment of all applicable fees, NeoGenesis hereby grants to OGS,
and OGS hereby accepts, an exclusive, worldwide, right and license, within the
Territory and within the Field, to use the NeoGenesis Know-How and NeoGenesis
Patent Rights and NeoGenesis's undivided interest in any Program Intellectual
Property that is jointly owned by NeoGenesis and OGS pursuant to the provisions
of Section 3.2, as embodied in or related to any Designated Compound(s)
(collectively, the LICENSED TECHNOLOGY), to (i) research, develop, make, have
made and use such Designated Compound to develop Licensed Products and (ii) to
make, have made, use, distribute for sale, promote, market, offer for sale,
sell, have sold, import and export Licensed Products. OGS may grant sublicenses
of its rights under this Section 3.1; PROVIDED that OGS: (1) obtains each
sublicensee's written agreement to be subject to obligations at least equivalent
to those that OGS is subject to under Sections 2.10, 2.11, 3.1(c), 3.2, 4.5,
4.7, 4.7A, 4.8, 5.2 and 8.3(c) (last sentence) of this Agreement, (2) uses
reasonable endeavours to obtain each sublicensee's written agreement to be
subject to obligations at least equivalent to those that OGS is subject to under
Sections 7.2(b), 7.3(b) and 7.4 of this Agreement and (3) shall remain
responsible for the performance of all of its obligations under this Agreement,
whether such obligations are performed by OGS, its Affiliates or any of its
sublicensees.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

     (b) The license granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that OGS
may elect to retain and may fully exercise all of its rights and elections under
the Bankruptcy Code PROVIDED, that it abides by the terms of this Agreement.

     (c) OGS shall mark or have marked all containers or packages of Licensed
Products that are the subject of the license granted under this Section 3.1 in
accordance with the patent marking laws of the jurisdiction in which such
Licensed Products are manufactured, used or sold.

3.2  OWNERSHIP RIGHTS.

     (a)(i) NEOGENESIS EXISTING INTELLECTUAL PROPERTY. This Agreement does not
convey to OGS any ownership rights in any NeoGenesis Know-How or NeoGenesis
Patent Rights by implication, estoppel or otherwise except for the rights
expressly granted in Section 3.1 and specifically does not convey to OGS any
rights with respect to ALIS or QSCD. Title to the NeoGenesis Know-How and
NeoGenesis Patent Rights shall at all times remain vested in NeoGenesis.

     (a)(ii) OGS EXISTING INTELLECTUAL PROPERTY. This Agreement does not convey
to NeoGenesis any ownership rights in any OGS Know-How or OGS Patent Rights by
implication, estoppel or otherwise except for the rights expressly granted in
Section 2.3. Title to the OGS Know-How and OGS Patent Rights shall at all times
remain vested in OGS.

     (a)(iii) PROGRAM INTELLECTUAL PROPERTY. Title to and any interest in
Program Intellectual Property described in clause (c) of the Program
Intellectual Property definition shall be the sole and exclusive property of OGS
and is included in the definition of OGS Know-How or OGS Patent Rights, as the
case may be. Title to and any interest in Program Intellectual Property
described in clause (a) of the Program Intellectual Property definition shall be
the sole and exclusive property of NeoGenesis and is included in the definition
of NeoGenesis Know-How or NeoGenesis Patent Rights, as the case may be. Title to
and any interest in Program Intellectual Property described in clause (b) of the
Program Intellectual Property definition shall be jointly held by OGS and
NeoGenesis. Notwithstanding any of the foregoing, Program Intellectual Property,
regardless of inventorship, shall be (i) the property of NeoGenesis if such
Program Intellectual Property is directly related to NeoGenesis' proprietary
mass encoded NeoMorph compound library, ALIS screening technology or QSCD; and
(ii) the property of OGS if such Program Intellectual Property is directly
related to the Targets or the uses thereof or to OGS's functional or secondary
assays, or to the Licensed Products.

     (b) INVENTORSHIP. Patent counsel mutually acceptable to the parties and
selected by the Steering Committee in accordance with Section 3.3(c) shall
determine inventorship of all Program Intellectual Property in accordance with
U.S. patent law (and other U.S. intellectual property law) when determining
whether such intellectual property is (i) OGS Know-How or OGS Patent Rights or
(ii) NeoGenesis Know-How or NeoGenesis Patent Rights or (iii) if such
intellectual property is Program Intellectual Property, whether Program
Intellectual Property is jointly owned or is owned solely by NeoGenesis or by
OGS.

     (c) RETAINED RIGHTS. NeoGenesis shall retain the following rights with
respect to the following NeoGenesis Know-How and NeoGenesis Patent Rights:

         (i) NeoGenesis shall continue to use its compound screening library to
         screen target proteins for other parties; PROVIDED, that during the
         Program Term with respect to any Target, NeoGenesis shall mask the
         Preliminary Compounds that are in the Chemotype of the Designated
         Compound(s) relating to such Target from the NeoGenesis NeoMorph
         Screening Library.

         (ii) NeoGenesis shall continue to use Primary Active Compounds and
         Selected Compounds that are not selected as Designated Compounds, as
         embodied in focused/optimization libraries developed as part of the
         Program to support NeoGenesis patent applications outside the
         transactions contemplated by the Program.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

         (iii) NeoGenesis shall retain all rights and continue to use
         optimization compounds created as part of the Program but not selected
         as Primary Active Compounds or Selected Compounds.

         (iv) NeoGenesis shall retain all rights in and continue to use compound
         libraries that are designed as part of the Program using QSCD or other
         structural information.

3.3 DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and OGS shall
disclose to the other the conception or reduction to practice, or the discovery,
development or making of any Program Intellectual Property; such Program
Intellectual Property will be added to ATTACHMENT B (and ATTACHMENT D if
applicable) and will be subject to the provisions of this Agreement. Within
forty-five (45) days following the date of such disclosure regarding the
existence of particular Program Intellectual Property that is either (i) solely
owned by NeoGenesis, but only to the extent that such Program Intellectual
Property relates to the structure of any of the Selected Compounds (during the
period prior to designation pursuant to Section 2.6) or Designated Compounds; or
(ii) jointly owned by the parties, the Steering Committee shall confer as to the
appropriate protection (if any) for such Program Intellectual Property. With
respect to the Program Intellectual Property described Section 3.3(a)(i), such
determination shall be made having reference to the likelihood that seeking
patent protection will adversely effect future filings by OGS with respect to
new chemical entities based upon such Designated Compound (or such Selected
Compounds if the period for designation has not then expired). In the event that
the Steering Committee is unable to reach unanimous agreement on whether patent
protection should be sought, the provisions of Section 2.5(d) shall not apply
and the parties agree that the dispute shall be governed by the provisions of
Section 9.1.

     (b) Subject only to the provisions of Section 3.3(a) above (to the extent
applicable), NeoGenesis shall have the sole right, but not the obligation, to
file, prosecute, and maintain each of the NeoGenesis Patent Rights throughout
the Territory. OGS shall reimburse NeoGenesis for all reasonable, out-of-pocket
expenses incurred by NeoGenesis for the filing, prosecution and maintenance of
NeoGenesis Patent Rights that arise from Program Intellectual Property and are
the subject of the exclusive license granted OGS under Section 3.1 but
specifically excluding reimbursement for any costs associated with NeoGenesis
Patent Rights in existence at the Effective Date including, without limitation,
ALIS or QSCD or other NeoGenesis Patent Rights that are not the subject of such
exclusive license. If any NeoGenesis Patent Rights that are the subject of OGS
reimbursement are subsequently licensed to any other Person, NeoGenesis shall
collect patent expenses from such third party and reimburse OGS a proportionate
amount of the patent expenses that OGS previously funded, with such
proportionate amount being determined with reference to the aggregate number of
licensees of such NeoGenesis Patent Rights. OGS shall not be required to
reimburse NeoGenesis with respect to any patent costs concerning the NeoGenesis
Patent Rights that are the subject of the exclusive license granted OGS under
Section 3.1; PROVIDED, that OGS's license shall exclude any intellectual
property rights that are the subject of such action (e.g., patent coverage in a
particular country) unless and until OGS reimburses NeoGenesis for such costs.
NeoGenesis shall promptly invoice OGS for all reasonable expenses incurred in
relation to these activities. In the event that NeoGenesis elects not to file
for patent protection under the NeoGenesis Patent Rights or elects not to
prosecute or maintain a patent or patent application under the NeoGenesis Patent
Rights (hereafter REJECTED RIGHTS) it shall notify OGS of such decision at least
forty-five (45) days prior to the due date of any action or payment due. OGS
shall have the right, but not the obligation to assume the responsibility
therefor then at its own cost and expense. In the event that OGS elects to
assume responsibility for the prosecution and maintenance of Rejected Rights,
such Rejected Rights shall automatically be removed from the scope of the
exclusive license granted under Section 3.1. NeoGenesis shall keep OGS currently
advised as to the status of all patents and patent applications with respect to
the NeoGenesis Patent Rights and shall supply OGS promptly with copies of all
patents, patent applications, substantive patent office actions, substantive
responses received or filed in connection with such applications. OGS may itself
or through its attorney offer comments and suggestions with respect to the
matters that are the subject of this Section 3.3(b) and NeoGenesis agrees to
consider such comments and suggestions in good faith. Any differences between
NeoGenesis and OGS with respect to preparation, filing, prosecution, issuance
and maintenance matters will be discussed and resolved to their mutual
satisfaction using the procedures specified in Section 9.1, if necessary.

     (c) Subject only to the provisions of Section 3.1(a) above, OGS and
NeoGenesis, acting through the Steering Committee, shall select and retain
patent counsel mutually acceptable to each of them for the purpose of preparing,
filing, prosecuting, issuing and maintaining appropriate patent applications
concerning jointly owned Program Intellectual Property. The parties, acting in
consultation, shall be responsible for the preparation, filing (including

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

foreign filing decisions), prosecution and maintenance of such patent
applications and patents relating to jointly owned Program Intellectual
Property. The parties shall ensure that patent counsel provides each party with
copies of documents relevant to the same and each party shall have the
opportunity to review and comment on patent decisions made by patent counsel.
Any differences between NeoGenesis and OGS with respect to preparation, filing,
prosecution, issuance and maintenance matters will be discussed and resolved to
their mutual satisfaction using the procedures specified in Section 9.1, if
necessary; PROVIDED, that if any disagreement regards the costs associated with
a particular proposed action, OGS may assume responsibility for such costs and
the requirement that the parties mutually agree upon resolution of the matter
shall not apply. OGS shall be responsible for all expenses associated with the
preparation, filing, prosecution, issuance and maintenance of patents or other
intellectual property protection for jointly owned Program Intellectual
Property; PROVIDED, that in the event that OGS elects not to pursue a particular
action with respect to which the parties disagree regarding costs, NeoGenesis
shall have the right to assume such costs and to have such action taken;
PROVIDED FURTHER that OGS's license shall exclude any intellectual property
rights that are the subject of such action (e.g., patent coverage in a
particular country) unless OGS reimburses NeoGenesis for the costs of such
action.

     (d) OGS shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at OGS's sole expense, each of the OGS Patent Rights
throughout the Territory.

3.4 ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights but excluding
Licensed Technology within the Territory UNLESS legal proceedings with respect
to such Licensed Technology also materially affect intellectual property rights
of NeoGenesis that relate to other then active NeoGenesis research, development
or commercialization programs. OGS shall be solely responsible for the defense
and enforcement of OGS Know-How and OGS Patent Rights.

     (b) Except as otherwise provided in Section 3.4(a), OGS shall have the
first option to pursue any enforcement or defense of Licensed Technology within
the Territory; PROVIDED, that OGS pays all costs and expenses related to the
same, keeps NeoGenesis reasonably informed of its progress and provides
NeoGenesis with copies of any material documents related to such proceedings and
reasonable notice of all proceedings relating to same. OGS's costs in
prosecuting such matters shall be subject to reimbursement in accordance with
Section 3.4(d). OGS shall notify NeoGenesis of its decision to exercise its
right to enforce Licensed Technology as soon as possible, but not later than
ninety (90) days following its discovery or receipt of notice of the alleged
infringement.

     (c) If OGS does not exercise its option to enforce or defend any Licensed
Technology or (within ninety (90) days of commencing to prosecute any
enforcement or defense action) OGS and NeoGenesis have not otherwise agreed not
to pursue such infringement for business reasons, and OGS (i) has not persuaded
the alleged infringer to desist, (ii) is not diligently pursuing an infringement
action or diligently defending the validity or enforceability of Licensed
Technology at issue, as determined by NeoGenesis in its reasonable discretion,
or (iii) has not provided NeoGenesis with evidence of bona fide negotiations of
an acceptable sublicense agreement with the alleged infringer, then NeoGenesis
shall have the right to pursue the alleged infringer or take control of any
action initiated by OGS at NeoGenesis's own expense. In any such case, OGS will
substitute NeoGenesis as party plaintiff for purposes of pursuing any alleged
infringer.

     (d) Any recovery of damages with regard to Licensed Technology in any suit
handled by one party pursuant to Section 3.4(b) or Section 3.4(c) shall be
applied first in satisfaction of any unreimbursed expenses and legal fees of the
litigant relating to the suit or settlement thereof. The balance, if any
remaining after the litigant has been compensated for expenses shall be paid (1)
one hundred percent (100%) to NeoGenesis if NeoGenesis is the prosecuting party
or (2) one hundred percent (100%) to OGS if OGS is the prosecuting party;
PROVIDED that (i) any recovery of ordinary damages based upon infringement of
Licensed Technology shall be deemed to be Net Sales and OGS shall pay NeoGenesis
an amount calculated in accordance with Section 4.4 to reimburse NeoGenesis for
royalties due in respect of lost sales of Licensed Products represented by such
ordinary damages; and (ii) the allocation described in Section 3.4(d)(i) shall
not apply as to special or punitive damages. If the parties jointly participate
(other than the assistance that each party is required to provide to the
litigating party pursuant to Section 3.4(b) or Section 3.4(c), as the case may
be, and for which it has been reimbursed) in prosecuting legal proceedings
relating to infringement of the Licensed Technology, any damages and costs
received in any proceedings or by way of settlement shall be shared by the
parties as follows: (A) the actual costs and expenses of all suits brought by
either

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

party shall be reimbursed, first to the filing party and then to the
participating party; and (B) any remaining damages shall be split fifty percent
(50%) to NeoGenesis and fifty percent (50%) to OGS. No settlement, or consent
judgment or other voluntary final disposition of any suit regarding Licensed
Technology may be entered into without the consent of the other party, which
consent shall not be unreasonably withheld.

     (e) Notwithstanding the provisions of Section 3.4(b), in the event that a
declaratory judgment action alleging invalidity or non-infringement of any of
the patents within Licensed Technology that are within NeoGenesis Patent Rights
but are not within jointly owned Program Intellectual Property, NeoGenesis shall
have the first option, within ninety (90) days after notification of same, to
assume defense of the action concerning its own technology at its expense, but
OGS shall be entitled to participate in such action, at its own expense.

     (f) In any infringement suit as either party may institute to enforce
Licensed Technology, or in any declaratory judgment action alleging invalidity
or non-infringement of any Licensed Technology brought against NeoGenesis or
OGS, the other party shall, at the request and expense of the party initiating
or defending the suit or action, cooperate and assist in all reasonable
respects, including being named as a party if necessary, having its employees
testify when requested and making available relevant records, papers,
information, specimens and the like.

     (g) Notwithstanding any provisions of Section 3.4 to the contrary, each
party shall immediately give written notice to the other of any certification
of which it becomes aware filed pursuant to the Waxman-Hatch Act (21 U.S.C.
Section 355(b)(2)(A), or Section 355(j)(2)(A)(vii)), or any amendment or
successor statute thereto, at least fourteen (14) days prior to expiration of
the forty five (45) day period set forth in 21 U.S.C. Section 355(c)(3)(c)
(or any amendment or successor statute thereto), then OGS shall have the
right to bring such an infringement action, in its sole discretion and at its
own expense, in its own name and/or in the name of NeoGenesis. Any recoveries
obtained (by settlement or otherwise) by either party as a result of any
proceeding against a third party infringer brought under this Section 3.4(g)
shall first be used to reimburse each party for all litigation costs in
connection with such proceeding paid by that party and second, any remainder
shall be paid (x) one hundred percent (100%) to NeoGenesis if NeoGenesis is
the prosecuting party or (y) one hundred percent (100%) to OGS if OGS is the
prosecuting party; PROVIDED that (i) any recovery of ordinary damages based
upon infringement of Licensed Technology shall be deemed to be Net Sales and
OGS shall pay NeoGenesis an amount calculated in accordance with Section 4.4
to reimburse NeoGenesis for royalties due in respect of lost sales of
Licensed Products represented by such ordinary damages; and (ii) the
allocation described in Section 3.4(g)(i) shall not apply as to special or
punitive damages. If OGS or its sublicensee initiate suit pursuant to this
Section 3.4(g), it will promptly notify NeoGenesis.

4.  PRICING; PAYMENT

4.1 EQUITY PURCHASE. OGS agrees to subscribe for and purchase, and NeoGenesis
agrees to authorize and issue to OGS, an aggregate six million United States
dollars (US$6,000,000) worth of Series E (non-voting) Preferred Stock, $.001 par
value per share, at a price of five and 97/100's United States dollars (US$5.97)
per share. Such equity investment shall be made pursuant to a separate Series E
Preferred Stock Purchase Agreement containing mutually acceptable terms. Such
equity subscription shall be made within thirty (30) days following the
Effective Date unless the parties agree to extend the time for the consummation
of such subscription.

4.1A INITIAL PAYMENT. In consideration of the rights granted to it pursuant to
this Agreement and for NeoGenesis agreeing to provide the services more
particularly set out in this Agreement, OGS will pay to NeoGenesis the sum of
[*] within [*] of the Effective Date.

4.1B BONUS PAYMENT. OGS agrees to pay to NeoGenesis the sum of [*] upon
provision to OGS by NeoGenesis of the Selected Compounds [*]. Such payment shall
be made within [*] of notification of such completion by NeoGenesis.

4.2 FTE BASED R&D FUNDING. The Steering Committee shall agree upon the number of
NeoGenesis FTEs to be assigned to the conduct of the Program in each calendar
year (subject to a maximum of [*]. Such staffing level shall be established
prior to the commencement of each year of the Program and shall equal [*] FTEs
for the initial year of the Program. OGS shall provide NeoGenesis with funding
for the budgeted FTEs for each year of the Program at an annual rate of [*] per
FTE, it being understood that the expected annual funding obligation shall equal
[*] FTEs during each year of the Program but that the number of FTEs during the
initial year of the Program may be less than

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

[*] and that the budgeted number of FTEs in subsequent years of the Program will
exceed [*] FTEs s that the aggregate FTE funding obligation during the [*]
funding period equals [*] FTEs. Payment under this Section 4.2 shall be made by
OGS quarterly in advance; PROVIDED, that the initial installment will be paid
within [*] of the Effective Date. If in any quarterly funding period, actual
expenditures by NeoGenesis with respect to FTEs exceed the amount budgeted for
the period, the overrun will be carried forward for the next period and paid for
from the next payment(s); PROVIDED, that OGS payment obligations for any year of
the Program shall not exceed the budgeted amount for such year UNLESS OGS has
agreed to fund additional FTE work beyond that budgeted for such year by means
of a written amendment to such budget approved in writing by the parties. If in
any period actual expenditures are less than the amount budgeted for the period,
the underrun may be applied to the expenses of the subsequent periods by
NeoGenesis but shall not reduce the amount due NeoGenesis from OGS for the
subsequent period(s). In addition, should OGS require NeoGenesis to conduct any
lead optimisation services in respect of any Designated Compound, the parties
shall meet to discuss the terms upon which NeoGenesis would be willing to
provide such services.

4.2B TREATMENT OF FUNDS. NeoGenesis shall monitor expenditures, in accordance
with its corporate policies, to ensure that the funds provided by OGS are spent
in accordance with this Agreement. NeoGenesis shall keep and maintain adequate
books and records to furnish complete and accurate information to OGS regarding
calculation of the amounts expended by NeoGenesis on the Program according to
the provisions of this Agreement. During the Program Term and for three (3)
years following the expiration of the Program Term, NeoGenesis shall permit OGS
to examine such books and records during normal business hours, upon thirty (30)
days notice to NeoGenesis. Upon the expiry of the three (3) year period, the
calculation of the amounts expended on each year of the Program shall be binding
and conclusive upon the parties and NeoGenesis shall be released from any
further accountability with respect to the Program.

4.3  MILESTONES.

(a) OGS will pay NeoGenesis milestone payments in respect of the [*] Licensed
Products as specified below:

         (i)  Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase I Clinical Trial relating to such Licensed Product,
              OGS will pay NeoGenesis [*]. PHASE I CLINICAL TRIALS means any
              human clinical trials, the principal purpose of which is a
              preliminary determination of safety of a Licensed Product for its
              intended use in healthy individuals or patients to support its
              continued testing in similar clinical trial prescribed by the
              relevant Regulatory Authorities.

         (ii) Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase II Clinical Trials relating to any Licensed Product,
              OGS will pay NeoGenesis [*]. PHASE II CLINICAL TRIALS means any
              human clinical trials for which a Primary Endpoint is a
              preliminary determination of safety, biological activity, efficacy
              or dose ranges in patients with the disease target being studied
              (as specified in the Field specified by OGS at the time it submits
              such Target pursuant to Section 2.1) as required by the relevant
              Regulatory Authorities. PRIMARY ENDPOINT means, with respect to a
              Phase II Clinical Trial, the point at which positive statistical
              significance has been achieved with respect to the primary
              endpoint specified in the protocol for such trial.

         (iii)Within thirty (30) days following the date on which the first
              administration or dosing of any Licensed Product occurs in the
              first Phase III Clinical Trials relating to such Licensed Product,
              OGS will pay to NeoGenesis [*]. PHASE III CLINICAL TRIALS means a
              human clinical trial the principal purpose of which is to
              establish safety and efficacy of a Licensed Product in patients
              with the disease target being studied (as specified in the Field
              specified by OGS at the time it submits such Target pursuant to
              Section 2.1)as required by the relevant Regulatory Authorities.

         (iv) Within thirty (30) days following the date on which OGS submits a
              NDA covering any Licensed Product with the FDA, or makes a
              comparable filing with regulatory authorities in another Major
              Country, OGS will pay NeoGenesis [*].

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                      14
<Page>

         (v)  Within thirty (30) days following the date on which OGS receives a
              NDA approval or equivalent Regulatory Approval from the FDA
              permitting the manufacture and sale of a Licensed Product or a
              comparable Regulatory Approval for another Major Country, OGS will
              pay NeoGenesis [*].

(b) OGS will pay NeoGenesis milestone payments in respect of any subsequent
Licensed Products (not falling within the provisions of Section 4.3(a) above) as
specified below:

         (i)  Within thirty (30) days following the date on which OGS submits a
              NDA covering any Licensed Product with the FDA, or makes a
              comparable filing with regulatory authorities in another Major
              Country, OGS will pay NeoGenesis [*].

         (ii) Within thirty (30) days following the date on which OGS receives a
              NDA approval or equivalent Regulatory Approval from the FDA
              permitting the manufacture and sale of a Licensed Product or a
              comparable Regulatory Approval for another Major Country, OGS will
              pay NeoGenesis [*].

(c) On the date any one milestone with respect to a Licensed Product is
achieved, all lower numbered unachieved milestones shall be deemed to have been
achieved with respect to that Licensed Product; PROVIDED that with respect to
the milestone specified in Section 4.3(a)(ii), no payment of such milestone
amount shall be due upon the achievement of the milestone specified in Section
4.3(a)(iii) if Phase II Clinical Trials are not required but such milestone
shall be paid upon the achievement of the milestone specified in Section
4.3(a)(iv).

4.4 ROYALTIES. Not later than forty-five (45) days following each March 31, June
30, September 30 and December 31 (each such 13-week period, a CALENDAR QUARTER)
commencing with the First Commercial Sale of Licensed Products in any country,
OGS shall pay to NeoGenesis royalties by country for the most recent Calendar
Quarter then ended, equal to:

         (i) [*] of Net Sales if NeoGenesis is not instructed to conduct lead
         optimization  activities with regard to the relevant Licensed Product;
         or

         (ii) [*] of Net Sales if NeoGenesis is instructed to conduct lead
         optimization activities with regard to the relevant Licensed Product.

4.4A SUBLICENSE FEES AND ROYALTIES. (a) In the event that OGS sublicenses the
development and commercialization of a Licensed Product to a third Person, OGS
shall pay NeoGenesis (i) [*] of any sublicense fees, milestone payments or other
consideration (excluding royalties) received by OGS during the term of such
sublicense, if NeoGenesis does not perform lead optimisation activities with
regard to the applicable Licensed Product; and (ii) [*] of any sublicense fees,
milestone payments or other consideration (excluding royalties) received by OGS
during the term of such sublicense if NeoGenesis does perform lead optimisation
activities with regard to the applicable Licensed Product; PROVIDED, that the
aggregate consideration paid to NeoGenesis in respect of each Licensed Product
that is the subject of such sublicense shall not exceed [*]. Equity purchases of
OGS securities by a sublicensee shall not be considered to be sublicense fees
provided that fair and commercially reasonable sublicense fees are collected in
conjunction with such transactions.

     (b) In the event that OGS sublicenses the development and commercialization
of a Licensed Product to a third Person, OGS shall pay NeoGenesis (i) [*] of any
royalties received by OGS during the term of such sublicense, if NeoGenesis does
not perform lead optimisation activities with regard to the applicable Licensed
Product; and (ii) [*] of any royalties received by OGS during the term of such
sublicense if NeoGenesis does perform lead optimisation activities with regard
to the applicable Licensed Product; PROVIDED, that the royalty rate due on
sublicensee sales of Licensed Products shall not exceed (1) [*] of such
sublicensee's Net Sales of Licensed Products in cases where NeoGenesis does not
perform lead optimisation activities with regard to the applicable Licensed
Product or (2) [*] of such sublicensee's Net Sales of Licensed Products in cases
where NeoGenesis does perform lead optimisation activities with regard to the
applicable Licensed Product.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

4.4B ROYALTY STACKING. If OGS obtains one or more licenses under patents owned
by a third party to avoid infringement by any Licensed Product of such third
party patent(s), OGS may, beginning from the date of such third party license,
deduct [*] of the amount of royalties paid to such third party on sales of
Licensed Product under such licenses, provided that: (i) such infringement is
primarily due to the Designated Compound as licensed by NeoGenesis and not
related to changes or additions to the Designated Compound made by a party other
than NeoGenesis and (ii) such deductions reduce by no more than [*] the
royalties otherwise due NeoGenesis under Section 4.4 with respect to such
Licensed Product.

4.5 ROYALTY TERM. OGS shall pay any royalties due with respect to each Licensed
Product on a country by country basis until the date which is the later of (i)
the expiration or revocation or complete rejection of the last to expire or to
be revoked or to be completely rejected of any NeoGenesis Patent Right covering
such Licensed Product in the country in which the Licensed Product is
Commercialized, or (ii) if no NeoGenesis Patent Right exists in the relevant
country covering the Commercialization of the relevant Licensed Product, until
ten (10) years from the First Commercial Sale of such Licensed Product in the
country in which the Licensed Product is Commercialized (ROYALTY TERM). Upon
expiry of the Royalty Term, OGS's license under Section 3.1 shall be deemed to
be fully paid and OGS shall be able to continue Commercialization of the
relevant Licensed Product in the relevant country(ies) without any further
liability to NeoGenesis.

4.5A SAMPLES AND DONATIONS. No royalties shall accrue on the disposition of
Licensed Product at cost or without charge by OGS as (a) samples (promotion or
otherwise) or as donations (to non-profit institutions or government agencies
for a non-commercial purpose) or (b) for clinical studies or (c) as donations
(to non-profit institutions or government agencies for clinical purposes) of
Licensed Product. Such dispositions by OGS shall not be included in the
determination of Net Sales but shall be recorded in the royalty report to be
submitted pursuant to Section 4.7A.

4.6 REMITTANCE. (a) All royalties and milestone payments required under this
Section 4 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales are made. For the purpose of
computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
simple average of all Mondays' exchange rate for buying United States Dollars
set forth in THE WALL STREET JOURNAL for the calendar quarter in which such
sales were made.

     (b) In the event that any payment due to NeoGenesis under this Agreement is
not made when due, NeoGenesis shall be entitled, but not obliged, to demand
interest on the amount due, which interest shall accrue beginning on the
fifteenth (15th) day following the final date on which such payment was due,
calculated at the annual rate equal to two percent (2%) above the prime interest
rate reported in the WALL STREET JOURNAL for the due date, calculated from the
due date until paid in full. Such payment when made shall be accompanied by all
interest so accrued. Said interest and the payment and acceptance thereof shall
not negate or waive the right of NeoGenesis to any other remedy, legal or
equitable, to which it may be entitled because of the delinquency of the
payment.

     (c) If at any time legal restrictions imposed by any national authority
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by OGS of any royalties owed by
OGS to NeoGenesis in respect of sales in such country is prevented, the parties
shall consult with a view to finding a prompt and acceptable solution, and OGS
shall make payment through any lawful means or methods that may be available as
NeoGenesis shall reasonably request at no additional out-of-pocket expense to
OGS Notwithstanding the foregoing, if royalties in any country cannot be
remitted to NeoGenesis for any reason within three (3) month after the end of
the relevant Calendar Quarter, then OGS shall pay NeoGenesis in the local
currency of such country by deposit of the relevant royalties in a bank account
in such country designated by NeoGenesis.

4.7 RETENTION OF RECORDS. OGS, its Affiliates and sublicensees shall keep and
maintain for a period of at least three (3) years from the date of each payment
of royalties, records (prepared in accordance with United Kingdom Generally
Accepted Accounting Principles, consistently applied) sufficient to determine
the amounts of Net Sales and payments due under Section 4.3. Upon the expiry of
the three (3) year period, the calculation of royalties payable under this
Agreement in respect of such previous Calendar Quarters shall be binding and
conclusive upon the parties and OGS shall be released from any further
accountability with respect to such Calendar Quarters.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

4.7A ROYALTY REPORTS. Within forty-five (45) days following each Calendar
Quarter in which payments are due under Section 4.3, OGS shall provide
NeoGenesis with a report including at least: (a) the quantities of Licensed
Products that OGS, its Affiliate(s) and sublicensee(s) sold during the preceding
quarter in each country in which Licensed Products or package products
containing Licensed Products were sold; (b) the quantity of samples and
donations disposed of during the preceding quarter; (c) the monetary amount, in
the national currency of such country, of such sales; (d) actual Net Sales, by
country; (e) the currency conversion rate used and U.S. dollar-equivalent of
such sales; (f) the calculation of royalties thereon; and (g) the total
royalties so computed and due NeoGenesis. The obligation to submit reports shall
only commence upon the First Commercial Sale of a Licensed Product in a country
and thereafter such reports shall be submitted to NeoGenesis whether or not any
sales of Licensed Product have been made during such period. Upon delivery of
the report due for the period ending December 31 of each year, OGS shall also
report to NeoGenesis the aggregate royalties due NeoGenesis for the entire
preceding year.

4.8 INSPECTION. OGS and its Affiliates shall, and OGS shall procure that its
sublicensees shall, each make its records available for inspection by an
independent certified public accountant appointed by NeoGenesis and reasonably
acceptable to OGS during regular business hours at such place or places where
such records are customarily kept, upon reasonable notice from NeoGenesis,
solely to verify the accuracy of the reports and payments. Such inspection right
shall not be exercised more than once in any calendar year nor more than once
with respect to sales of Licensed Products in any given payment period.
NeoGenesis agrees to hold in strict confidence all information concerning
royalty payments and reports, and all information learned in the course of any
audit or inspection, except to the extent necessary for NeoGenesis to reveal
such information in order to enforce its rights under this Agreement. Any person
or entity conducting such audit or inspection will agree in writing with
NeoGenesis to treat all records reviewed in the course of the audit or
inspection as the Confidential Information of OGS under terms and conditions no
less restrictive than the terms contained in Section 5.2. Save in the case of
manifest error, the results of each inspection, if any, shall be binding on both
parties. NeoGenesis shall pay for such inspections, except that in the event
there is any upward adjustment in aggregate royalties payable for any year shown
by such inspection of more than five percent (5%) of the amount paid, OGS shall
pay for such inspection.

4.9 TAXES. If at any time, any jurisdiction within the Territory requires OGS to
withhold income taxes or other taxes from the amounts paid NeoGenesis pursuant
to this Agreement and to pay the taxes for the account of NeoGenesis, OGS shall
make such withholding payments as required and subtract such withholding
payments from the payments set forth in this Agreement. OGS shall deliver to
NeoGenesis true copies of the receipts and/or returns covering all such
payments. To the extent that payments of withholding taxes made by OGS are based
upon financial information provided to OGS by NeoGenesis and, to the extent that
such information is incorrect or incomplete, NeoGenesis shall be liable for any
fine, assessment or penalty, or any deficiency, imposed by any taxing authority
in the Territory for any deficiency in the amount of any such withholding or the
failure to make such withholding payment. The parties will cooperate to
minimize, to the extent legally permissible, the tax liabilities related to this
Agreement. Notwithstanding the foregoing, such cooperation shall not cause any
adverse tax consequences to be incurred by either party which would not have
been incurred under the provisions of this Agreement, including this Section
4.9.

5.  CONFIDENTIALITY

5.1 PUBLICITY. Except as is necessary to comply with applicable laws and
regulations or to enforce their respective rights under this Agreement, or to a
party's legal or financial advisors, and except as otherwise agreed to by the
parties in writing, the parties shall: (a) keep the material terms of this
Agreement confidential; (b) agree upon the text and the exact timing of an
initial public announcement relating to the transactions contemplated by this
Agreement as soon as practicable after the Effective Date (such agreement not to
be unreasonably withheld or delayed); and (c) agree on the text and the timing
of any subsequent public announcements regarding this Agreement or the
transactions contemplated herein. Where consent to disclosure has been
previously obtained, either party shall be free to make further disclosures of
such information in the same or substantially similar form without the need for
any further advance approval. If this Agreement is required to be filed by
either party with the Securities and Exchange Commission or an equivalent
foreign Regulatory Authority, such party shall not file this Agreement with the
SEC or such other Regulatory Authority without first notifying the other party
and seeking confidential treatment

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

for any provisions of this Agreement that the other party believes would
disclose trade secrets, confidential commercial or financial information that
would impair the value of the contractual rights represented by this Agreement
or provide detailed commercial and financial information to competitors or third
parties. Nothing in this Section 5.1 shall prohibit disclosure of the terms of
this Agreement in the event and to the extent such disclosure is required by the
SEC or such other Regulatory Authority in the event the SEC or such regulatory
Authority rejects or requests modifications of an application for confidential
treatment request made pursuant to this Section 5.1.

5.2 CONFIDENTIALITY. (a) Confidential Information of each party will be used by
the other party solely for the purposes permitted by this Agreement. All
Confidential Information will be received and held in confidence by the
receiving party, subject to the provisions of this Agreement. Each party
acknowledges that it will not obtain any rights of any sort in or to the
Confidential Information of the other party as a result of such disclosure and
that any such rights must be the subject of separate written agreement(s).
Either party may only disclose the general nature, but not the specific
financial terms or the fact that OGS is pursuing any Targets that are the
subject of this Agreement, of this Agreement without the prior consent of the
other party; PROVIDED that either party may provide a copy of this Agreement or
disclose the terms of this Agreement (i) to any finance provider in conjunction
with a financing transaction, if such finance provider agrees to keep this
Agreement confidential, (ii) to any legal or financial advisor of such party, or
(iii) in response to a subpoena or other validly issued administrative or
judicial process requesting disclosure of same; PROVIDED, the party that
receives such order or process provides prompt notice to the disclosing party
before making any disclosure and permits the disclosing party to oppose or
narrow such request for disclosure and supports any of disclosing party's
reasonable efforts to oppose such request (at disclosing party's expense) and
shall disclose the terms of this Agreement only in the event of a final judgment
or administrative order requiring such disclosure, and only to the extent
necessary to comply with such request.

     (b) Each party will restrict disclosure of the other party's Confidential
Information to those of its directors, officers, employees, agents,
representatives, consultants, Affiliates and sublicensees to whom it is
necessary to disclose such Confidential Information in connection with the
purposes permitted under Section 5.2(a) and PROVIDED that any agents,
representatives, consultants and sublicensees are party to written agreements
that contain provisions consistent with the provisions of this Section 5.2 and
calculated to protect the confidentiality of the other party's Confidential
Information . Each party shall use reasonable efforts, including at least
efforts fully commensurate with those employed by the party for the protection
of its own Confidential Information, to protect the Confidential Information of
the other party.

     (c) Either disclosing party may at any time notify the receiving party that
such receiving party must return to the disclosing party the disclosing party's
Confidential Information. Each party hereby agrees to, within thirty (30) days
of such notification: (i) return all documents and tangible items it or its
employees or agents have received or created pursuant to this Agreement
pertaining, referring or relating to the other party's Confidential Information;
and (ii) return or certify (in a writing attested to by a duly authorized
officer of such party) destruction of all copies, summaries, modifications or
adaptations that such party or its employees or agents have made from the
materials provided by the disclosing party.

     (d) Nothing herein shall prevent a receiving party from disclosing all or
part of the Confidential Information as necessary pursuant to the lawful
requirement of a governmental agency (including, without limitation, the FDA and
other Regulatory Authorities involved in the approval or regulation of
pharmaceutical products) or when disclosure is required by operation of law;
PROVIDED that prior to any such disclosure to the extent permitted by law, the
receiving party shall use reasonable efforts to: (i) promptly notify the
disclosing party in writing of such requirement to disclose; and (ii) cooperate
fully with the disclosing party in protecting against any such disclosure or
obtaining a protective order.

6.  REPRESENTATIONS AND WARRANTIES.

6.1 AUTHORIZATION; ENFORCEABILITY. Each of OGS and NeoGenesis represent and
warrant to the other that: (a) it is a corporation or limited liability company,
as applicable, duly organized and validly existing under the laws of its
jurisdiction of organization and has all requisite power and authority to enter
into this Agreement; (b) it is duly authorized by all requisite action to
execute, deliver and perform this Agreement and to consummate the transactions

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

contemplated hereby, and that the same do not conflict or cause a default with
respect to such party's obligations under any other agreement; (c) it has duly
executed and delivered this Agreement; and (d) (i) it is authorized to disclose
any and all Confidential Information made available to the other party pursuant
to this Agreement; and (ii) it shall not disclose to the other party any
information that is confidential or proprietary to itself or to a third party
unless such information is identified as Confidential Information.

6.2 NEOGENESIS PERFORMANCE. NeoGenesis hereby represents and warrants to OGS
that: (a) NeoGenesis shall perform the Program using qualified personnel and in
a good and workmanlike manner consistent with industry standards of companies
that are comparable to NeoGenesis performing similar activities under similar
circumstances; and (b) as of the Effective Date, there is no agreement known to
NeoGenesis to which it is a party and by which it is bound that would conflict
with or be breached by NeoGenesis granting OGS the license in Section 3.1.

6.2A ADDITIONAL NEOGENESIS WARRANTIES AND REPRESENTATIONS. NeoGenesis hereby
represents and warrants to OGS that as of the Effective Date NeoGenesis is
unaware, without independent investigation, of any patents or trade secret
rights owned or controlled by any third Person which would be infringed by the
NeoGenesis Patent Rights or the NeoGenesis Know-How or the performance by
NeoGenesis of the services contemplated by this Agreement.

6.3 DISCLAIMER. (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2A, NeITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE NeoMorph Screening Library, the
NeoMorph Focused Libraries, QSCD, the Preliminary Compounds, the Primary Active
Compounds, the Selected Compounds, the DESIGNATED Compounds, THE TARGETS, THE
LICENSED PRODUCTS, THE NeoGenesis KNOW-HOW, THE OGS KNOW-HOW, THE SCOPE,
VALIDITY OR ENFORCEABILITY OF THE NeoGenesis PATENT RIGHTS OR THE OGS PATENT
RIGHTS, OR SUCH PARTy'S OBLIGATIONS UNDER THIS AGREEMENT.

     (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NeoGenesis AND OGS EXTEND
ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR DEMAND
AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN
SECTIONS 7.2-7.3.

7.  RISK ALLOCATION

7.1 LIMITATION OF LIABILITY. EXCEPT FOR INFRINGEMENT OF THE OTHER PARTY'S
INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER
SECTION 5 AND Except AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH RESPECT TO
third party claims, THE AGGREGATE LIABILITY OF EITHER PARTY FOR DIRECT DAMAGES
ARISING OUT OF THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE
LIMITED TO THE AGGREGATE AMOUNT PAID TO SUCH PARTY BY THE OTHER PARTY AS OF THE
DATE SUCH CLAIM IS FINALLY RESOLVED. EXCEPT FOR INFRINGEMENT OF THE OTHER
PARTY'S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY OBLIGATIONS
UNDER SECTION 5 AND Except AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH
RESPECT TO third party claims, IN NO EVENT SHALL either party be liable TO THE
OTHER for LOST PROFITS OR SAVINGS OR FOR ANY indirect, incidental,
consequential, special, PUNITIVE or exemplary damages IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, however caused,
under any theory of liability.

7.2 INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless OGS, its subsidiaries,
parent corporations, Affiliates, officers, directors, independent contractors,
partners, members, employees, agents, successors and assigns (each, in such
capacity an OGS INDEMNIFIED PARTY) from and against any claim, suit, demand,
loss, damage, expense (including reasonable

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

attorney's fees of indemnitee(s)) or liability (collectively, LOSSES) imposed
upon them by any third party and arising from or related to a third party claim
that (i) use of NeoGenesis Know-How or (ii) practice of the NeoGenesis Patent
Rights by OGS in accordance with the terms of this Agreement violates or
infringes the intellectual property rights of any third party. NeoGenesis shall
have no liability or obligation to OGS under this Section 7.2(a) in the event
and to the extent that the alleged infringement is caused by: (1) modifications,
alterations, combinations or enhancements of the Designated Compounds not
created by NeoGenesis, or (2) results from willful misconduct or negligent acts
or omissions of an OGS Indemnified Party.

     (b) Subject to the provisions of Section 7.4, OGS shall defend, indemnify
and hold harmless NeoGenesis, its subsidiaries, parent corporations, Affiliates,
officers, directors, independent contractors, partners, shareholders, employees,
agents, successors and assigns (each, in such capacity a NEOGENESIS INDEMNIFIED
PARTY) from and against any Losses imposed upon them by any third party and
arising from or related to a third party claim that (i) the R&D Program or any
modifications, alterations, combinations or enhancements of the Designated
Compounds; (ii) the use of the OGS Know-How, (iii) the practice of the OGS
Patent Rights, (iv) the Designated Compound or any Licensed Product; or (vii)
the Manufacture, development, testing, Commercialization, use or other
disposition of any of the foregoing, violates or infringes the intellectual
property rights of any third party. OGS shall have no obligation or liability to
NeoGenesis under this Section 7.2(b) in the event and to the extent that the
alleged infringement (1) is covered by Section 7.2(a) or (2) results from
willful misconduct or negligent acts or omissions of a NeoGenesis Indemnified
Party.

7.3 OTHER CLAIMS. (a) Subject to the provisions of Section 7.4, NeoGenesis will
defend, indemnify and hold harmless each OGS Indemnified Parties from and
against any Losses imposed upon the OGS Indemnified Party(s) by any third party
arising from or related to: (i) any material breach of the NeoGenesis's
representations and warranties under this Agreement; or (ii) any negligence or
intentional misconduct by NeoGenesis (or its employees, agents or
representatives) or by an Affiliate, licensee, sublicensee or agent in
performing its obligations under this Agreement, including the performance of
the Program. The foregoing indemnification action shall not apply in the event
and to the extent that a court of competent jurisdiction determines that such
Losses arose as a result of any OGS Indemnified Party's negligence, intentional
misconduct or breach of this Agreement.

     (b) Subject to the provisions of Section 7.4, OGS will defend, indemnify
and hold harmless each NeoGenesis Indemnified Party from and against any Losses
imposed upon the NeoGenesis Indemnified Party(s) by any third party arising from
or related to: (i) any material breach of OGS's representations and warranties
under this Agreement; (ii) any negligence or intentional misconduct by OGS (or
its employees, agents or representatives) or by an Affiliate, licensee,
sublicensee, distributor or agent of OGS in performing its obligations under
this Agreement, including the performance of the R&D Program; or (iii) the
labeling, packaging, package insert, other materials or promotional claims with
respect to any Licensed Product or the development, testing, Manufacturing,
Commercialization, use or other disposition of any Licensed Product by OGS or by
an Affiliate, licensee, sublicensee, distributor or agent of OGS. The foregoing
indemnification action shall not apply in the event and to the extent that a
court of competent jurisdiction determines that such Losses arose as a result of
any NeoGenesis Indemnified Party's negligence, intentional misconduct or breach
of this Agreement.

7.4 PROCEDURE. To receive the benefit of indemnification under Sections 7.2 or
7.3, the Indemnified Party must (a) promptly notify the party from whom
indemnification is sought (the INDEMNIFYING PARTY) in writing of a claim or
suit; PROVIDED, that failure to give such notice shall not relieve Indemnifying
Party of its indemnification obligations except where, and solely to the extent
that, such failure actually and materially prejudices the rights of Indemnifying
Party); (b) provide reasonable cooperation (at the Indemnifying Party's
expense); and (c) tender to the Indemnifying Party (and its insurer) full
authority to defend or settle the claim or suit; PROVIDED that no settlement
requiring any admission by the Indemnified Party or that imposes any obligation
on the Indemnified Party shall be made without the Indemnified Party's consent.
Neither party has any obligation to indemnify the other party in connection with
any settlement made without the Indemnifying Party's written consent. The
Indemnified Party has the right to participate at its own expense in the claim
or suit and in selecting counsel therefor. The Indemnified Party shall cooperate
with Indemnifying Party (and its insurer), as reasonably requested, at
Indemnifying Party's cost and expense.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

8.   TERM AND TERMINATION

8.1A PROGRAM TERM. This Agreement shall take effect as of the Effective Date and
shall remain in effect until the expiration date(s) specified in this Section
8.1, unless sooner terminated in accordance with Section 8.2. The Program will
remain in effect for a period of three (3) years from the Effective Date or such
longer period as is required for NeoGenesis to complete the Program in
accordance with Section 2.2(b) (the PROGRAM TERM), with an option by OGS to
renew for an additional one (1) year period on terms and conditions, including
level of support, that are mutually agreeable. OGS shall notify NeoGenesis
whether OGS wishes to negotiate to extend the Program for additional periods, no
later than ninety (90) days prior to termination of the initial Program Term.

8.1B ROYALTY TERM. If the license under Section 3.1 is exercised, such license
will remain in effect for the Royalty Term as specified in Section 4.5.

8.2 TERMINATION. (a) Either party may terminate the Program with thirty (30)
days notice to the other party if the other party fails to pay fees or patent
expenses due under the Agreement or commits a material breach unless the
nonpayment or breach is cured within the thirty (30) day notice period. In
addition, NeoGenesis may suspend work pursuant to the Program with notice to OGS
if OGS fails to pay NeoGenesis any amount due NeoGenesis under this Agreement.

     (b) Following completion of the Program, either party may terminate the
license with sixty (60) days notice if the other commits a material breach
unless the breach is cured within the sixty (60)-day notice period; PROVIDED
that such notice and cure period shall be reduced to thirty (30) days in the
case of payment obligations.

     (c) Either party shall have the right to terminate this Agreement with
thirty (30) days notice if a Force Majeure condition has prevented performance
by the other party for more than one hundred and twenty (120) consecutive days.
The parties may also terminate this Agreement at any time upon mutual written
agreement of the parties.

     (d)  OGS shall have the right to terminate this Agreement:

         (i) if, on the anniversary of the Project Commencement Date, OGS
reasonably determines that the conduct of the Program is failing to produce
successful results in respect of any of the Targets or that the scientific
rationale for continuing with the Program can no longer be sustained, then OGS
shall be entitled to terminate this Agreement upon the giving of thirty (30)
days written notice; or

         (ii) on each anniversary of the Effective Date with ninety (90) days
notice, if OGS reasonably determines that the conduct of the Program has
resulted in a minimal number of Compounds being identified as potential
candidates for drug development during the preceding twelve month period.

     (e) NeoGenesis shall have the right to terminate this Agreement if OGS
fails to make the equity investment contemplated by Section 4.1 within thirty
(30) days following the Effective Date.

8.3 EFFECT OF TERMINATION. (a) Upon termination (including expiration) of this
Agreement: (i) NeoGenesis will terminate all tasks for the Program in progress
at the date of termination in an orderly manner, as soon as practical and in
accordance with a schedule agreed to by OGS and NeoGenesis; (ii) NeoGenesis
shall deliver to OGS all materials developed through the termination of the
Program in accordance with the schedule agreed to by the parties pursuant to
Section 8.3(a); (iii) OGS shall pay NeoGenesis any monies due and owing
NeoGenesis up to the time of termination, for services actually performed
(including all work-in process (if any) pursuant to the last sentence of Item 7
or the last sentence of Item 8 of ATTACHMENT A); and (iv) within thirty (30)
days following termination (including expiration) of this Agreement, NeoGenesis
shall deliver to OGS a reasonably-detailed written report describing the results
of the research performed up to the date of such termination. In addition, if
OGS terminates this Agreement in accordance with Section 8.2(d) at any time
prior to the second anniversary of the Effective Date, NeoGenesis shall have the
right to repurchase from OGS within three (3) months following such termination,
all shares of NeoGenesis Series E Preferred Stock purchased by OGS (as
contemplated by Section 4.1), such repurchase to be at a price per share equal
to $5.97, as proportionately adjusted in the event that NeoGenesis effects a
stock split, stock combination or stock dividend. In addition, if NeoGenesis
terminates this Agreement pursuant to Section

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

8.2(e) or Section 9.6, NeoGenesis shall refund to OGS any funding received prior
to the date of such termination except to the extent such funding was used to
fund services actually performed prior to such termination.

     (b) Upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all documents and other tangible items it or its employees or
agents have received or created pertaining, referring or relating to the
Confidential Information of the other party.

     (c) The licenses granted by NeoGenesis under Section 3.1 shall survive any
expiration or termination of the Program or this Agreement with respect to any
Designated Compound or Licensed Product for which the applicable service fees
and milestone fees and royalties have been paid (when due in accordance with the
terms of this Agreement) and OGS shall continue to have the right to develop,
have developed, make, have made, use, distribute, offer for sale, import, export
and sell Licensed Products relating to such Designated Compounds; PROVIDED that
OGS continues to pay NeoGenesis milestone fees and royalties as required by
Sections 4.2 and 4.3 and complies with Sections 4.4-4.7. The licenses granted
under Section 3.1 shall not survive termination or expiration with respect to
Designated Compounds or Licensed Products for which OGS has not made payment in
accordance with this Agreement and shall immediately terminate with respect to
any Designated Compound or Licensed Product for which the applicable service
fees and milestone fees are not timely paid (should such payment become due
after termination of this Agreement or for any Licensed Product for which OGS
fails to pay NeoGenesis milestone fees and royalties as required by Sections 4.2
and 4.3 or fails to comply with Sections 4.4-4.7. In the event the license
granted to OGS under Section 3.1 terminates for any reason, each of OGS's
sublicensees at such time shall continue to have the rights and license set
forth in their sublicense agreements, PROVIDED such sublicensee agrees in
writing that NeoGenesis is entitled to enforce all relevant provisions directly
against such sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination. OGS's
liability for any charges, payments or expenses due to NeoGenesis that accrued
prior to the termination date shall not be extinguished by termination, and such
amounts (if not otherwise due on an earlier date) shall be immediately due and
payable on the termination date.

8.4 SURVIVAL. Sections 1, 2.6, 3.2, 3.3 and 4-9 shall survive any termination or
expiration of this Agreement.

9.  GENERAL PROVISIONS.

9.1 ISSUE RESOLUTION. (a) The parties shall use their best efforts to resolve
any controversy or dispute that arises under or relates to this Agreement
through good faith discussions. The parties shall initiate such discussions
using the following procedure. Either party shall notify the other party of the
nature of the controversy or dispute, providing sufficient detail to permit the
other party to understand same (a DISPUTE Notice). The representatives of the
parties shall meet within 30 days after the date that the non-sending party
receives the Dispute Notice to attempt to reach an agreement about the nature of
the dispute and a resolution of the dispute. If they are unable to resolve the
dispute within 60 days after their meeting, and do not agree to extend the time
period for resolving the dispute, or if the terms and conditions of the
resolution or settlement of the dispute are breached, the dispute shall be
resolved by arbitration pursuant to the provisions of Section 9.1(b). Pending
resolution of any dispute covered by this Section 9.1, both parties will
continue their performance under this Agreement including, without limitation,
the payment of all amounts due to the other party that are not in dispute.

     (b) Except in the case of a breach of Section 3.2 or Section 5.2, any
claim, dispute, or controversy arising out of or relating to this Agreement that
is not resolved in accordance with the provisions of Section 9.1(a) within the
time period specified in Section 9.1(a) will be submitted by the parties to
arbitration in accordance with the terms of Section 9.1(b)-(d); PROVIDED, that
actions by either party seeking equitable or declaratory relief may be brought
in court without resort to any of the provisions of Section 9.1(b)-(e). This
agreement to arbitrate shall continue in full force and effect despite the
expiration, rescission or termination of this Agreement.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

     (c) Any arbitration shall be conducted pursuant to the Commercial
Arbitration Rules of the International Chamber of Commerce (ICC) under the rules
then in effect for the ICC, as such rules may be modified by this Agreement or
by agreement of the parties. Any such arbitration shall be conducted in New York
City by one arbitrator. Each party irrevocably and unconditionally (i) consents
to the jurisdiction of any such proceeding and waives any objection that it may
have to personal jurisdiction or the laying of venue of any such proceeding; and
(ii) knowingly and voluntarily waives its rights to have disputes tried and
adjudicated by a judge and jury except as otherwise expressly provided herein.
The parties will cooperate with each other in causing the arbitration to be held
in as efficient and expeditious a manner as practicable. The parties will
attempt to agree upon a mutually acceptable arbitrator within 30 days of receipt
of the notice of intent to arbitrate. If the parties are unable to agree upon a
single arbitrator within such 30-day period or any extension of time which is
mutually agreed upon, three (3) arbitrators shall be used, one selected by each
party within ten (10) days after the conclusion of the 30-day period and a third
selected by the first two within ten (10) days thereafter. Unless the parties
agree otherwise, they shall be limited in their discovery to directly relevant
documents. Responses or objections to a document request shall be served twenty
(20) days after receipt of the request. The arbitrator(s) shall resolve any
discovery disputes. It is understood that the parties may (but are not required
to) submit disputes concerning any breach of Section 3.2 or Section 5.2 to
arbitration in accordance with this Section 9.1. Nothing herein shall prevent
the parties from settling any dispute by mutual agreement at any time.

     (d) Notwithstanding any provision of this Section 9.1 to the contrary, in
the event of a dispute between the parties relating to matters that are the
subject of section 3.3, the arbitration shall be performed by a single
arbitrator selected by the parties in accordance with Section 9.1(c) or by the
ICC in the event that the parties are unable to select a mutually acceptable
arbitrator and such arbitrator shall be a lawyer specialized in patent law and
admitted to practice in New York who is a partner or full member of a law firm
which has not been retained by or performed services for either party during the
three (3) year period prior to the date of alternative dispute resolution
initiation.

     (e) The arbitrator(s) shall apply the substantive laws of New York when
construing this Agreement and attempting to resolve any dispute relating to the
transactions contemplated by this Agreement, without regard for any choice or
conflict of laws rule or principle that would result in the application of the
substantive law of any other jurisdiction. The arbitration shall be of each
party's individual claims only, and no claim of any other party shall be subject
to arbitration in such proceeding. Except as otherwise required by law, the
parties and the arbitrator(s) shall maintain as confidential all information or
documents obtained during the arbitration process, including the resolution of
the dispute.

     (f) The arbitrator(s) shall not have the authority to award exemplary or
punitive damages, and the parties expressly waive any claimed right to such
damages. The arbitrator(s) shall have the authority to award actual money
damages (with interest on unpaid amounts from the date due) and may grant
equitable relief as is just and provided by the ICC Rules, in each case except
as specifically provided to the contrary herein The costs and expenses of the
arbitration, but not the costs and expenses of the parties, shall be shared
equally by the parties. Any award rendered by the arbitrator(s) shall be final
and binding upon the parties. Judgment upon the award may be entered in any
court of competent jurisdiction. If a party fails to proceed with arbitration,
unsuccessfully challenges the arbitration award, or fails to comply with the
arbitration award, the other party is entitled to costs, including reasonable
attorneys' fees, for having to compel arbitration or defend or enforce the
award.

9.2 GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the State of New York (except for Section
5-1401 of the New York General Obligations Law) to the exclusion of any choice
or conflict of laws rule or provision that would result in the application of
the substantive law of any other jurisdiction. Notwithstanding the foregoing,
the parties (and the arbitrators) shall use United States (Federal) patent and
copyright laws for purposes of governing and construing Sections 3.2-3.4 of this
Agreement. The United Nations Convention on Contracts for the International Sale
of Goods shall not apply to the transactions contemplated by this Agreement.

9.3 AMENDMENT AND WAIVER. No provision of or right under this Agreement shall be
deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

other party shall be effective as to any other breach, whether of the same or
any other term or condition and whether occurring before or after the date of
such waiver.

9.4 INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between OGS and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. NeoGenesis shall be solely responsible for compensating all its
personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes. OGS shall not provide NeoGenesis personnel
with any benefits, including but not limited to compensation for insurance
premiums, paid sick leave or retirement benefits.

9.5 ASSIGNMENT. Neither party may assign this Agreement or any of its rights and
obligations under this Agreement without the prior written consent of the other
party; PROVIDED, that either party may assign this Agreement to (a) any Person
to which such party transfers all or substantially all of its assets or with
which such party is consolidated or merged; (b) any Person that owns a majority
of the voting stock of such party; or (c) a single Person of which such party
owns a majority of the voting stock; PROVIDED, FURTHER, that in each instance
the assignee Person expressly assumes all obligations imposed on the assigning
party by this Agreement in writing and the other party is notified in advance of
such assignment and PROVIDED FURTHER that in the event that during the Program
Term: (i) the ownership or control of more than fifty percent (50%) of the
voting or income interest in NeoGenesis is acquired by another pharmaceutical
company that is reasonably regarded as a competitor of OGS, such determination
being made with reference to the products that such pharmaceutical company then
markets or for which it has made regulatory submissions with the FDA or an
equivalent Regulatory Authority in another Major Country or for which it has
publicly announced its intention to do either of the foregoing, or (ii)
NeoGenesis merges with another such pharmaceutical company, NeoGenesis shall
promptly notify OGS of the occurrence of such an event and either party shall
have the right, but not the obligation, to terminate this Agreement by serving
notice in accordance with the following provisions: (x) forthwith by notice in
writing in the case of OGS; and (y) upon twelve (12) months notice in writing in
the case of NeoGenesis (or upon expiration of the Program Term if the Program
Term sooner expires).

9.6 SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

9.7 NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
five (5) business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one
(1) business day after it is deposited with such courier), or sent by telefax
(such notice sent by telefax to be effective when sent (as evidenced by a
successful transmission receipt or equivalent), if confirmed by certified or
registered mail or overnight courier as aforesaid) to the address set forth on
the signature page to this Agreement or to such other place as any party may
designate as to itself by written notice to the other party.

9.8 SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court or arbitrator to replace any provision hereof so held
invalid, illegal or unenforceable with a valid provision which is as similar as
possible in substance to the invalid, illegal or unenforceable provision.

9.9 CAPTIONS. Captions of the sections and subsections of this Agreement are for
reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the terms
and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREOF and HEREUNDER refer to this
Agreement as a whole and not merely to a section or paragraph in which such
words appear, unless the context otherwise requires. The singular

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

shall include the plural, and each masculine, feminine and neuter reference
shall include and refer also to the others, unless the context otherwise
requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. In making proof of this Agreement, it shall not be
necessary to produce or account for more than one such counterpart.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation, other than a
payment obligation, created by this Agreement is caused by a Force Majeure
condition, that obligation shall be suspended during the continuance of the
Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

NEOGENESIS, INC.                     OXFORD GLYCOSCIENCES (UK) LIMITED

BY: /s/ Satish Jindal                BY: /s/ Michael L. Kranda
----------------------------------   -----------------------------------
Satish Jindal,  President and CSO    Michael L. Kranda, CEO
NOTICE ADDRESS:                      NOTICE ADDRESS:
NeoGenesis, Inc.                     Oxford GlycoSciences (UK) Limited
840 Memorial Drive                   The Forum, 86 Milton Park
Cambridge, MA 02139, USA             Abingdon, Oxon OX14 4RY, UK
Phone:   617.868.1500                Phone:  ++44 (0)1235 208000
Fax:     617.868.1515                Fax:    ++44 (0)1235 208010

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

                                  ATTACHMENT A

                                SCREENING PROGRAM

The Program to be performed by NeoGenesis with respect to the Targets will
screen compounds contained in the NeoGenesis NeoMorph Screening Library as
updated from time to time by NeoGenesis (collectively, such compounds are the
COMPOUNDS).

1. OGS will provide NeoGenesis with approximately [*] of each of the purified
functionally-active Target proteins for Target proteins delivered prior to
October 31, 2001 and will provide NeoGenesis with approximately [*] of each of
the purified functionally-active Target proteins for Target proteins delivered
on or after November 1, 2001. Each Target will be required to be of [*] (or
higher) purity (excluding micro-heterogeneity). Control experiments will be
performed with each of the OGS Targets to determine screening characteristics in
NeoGenesis' ALIS protocols. Follow-up control experiments will be performed
using OGS ligands (if available) to validate the retention of binding activity
of the Targets. SOPs will be established for ALIS screening based on the
preceding experiments. The Steering Committee will guide the selection of
Compounds to be screened against each Target including through the use of
CSD/QSC developed and in use at NeoGenesis.

2. Using the SOPs, NeoGenesis will perform ALIS screening of [*] Compounds
against each Target. The ALIS screening will be carried out to identify
Target-specific Compounds with that bind to the OGS Target with binding
affinities less than [*] micromolar (Kd LESS THAN [*]) (each such Compound is
referred to as a PRELIMINARY COMPOUND).

3. If NeoGenesis identifies a Preliminary Compound(s) for the Target and OGS is
able to provide NeoGenesis with a second protein that differs from the Target
but is of the same functional class of protein as the Target, NeoGenesis will
screen such second protein against the Preliminary Compound(s) to determine the
relative selectivity of the Preliminary Compound for the Target(s).
Alternatively, if OGS is unable to deliver a second protein of the same
functional class, NeoGenesis will screen an unrelated protein against the
Preliminary Compound(s) to assay the specificity of the initial Preliminary
Compounds.

4. NeoGenesis will synthesize up to [*] discrete compounds based upon the
Preliminary Compounds and subject them to ALIS for confirmation of binding to
the Target(s). NeoGenesis will deliver to OGS [*] of each of the discrete
compounds. OGS will perform Target-based functional assays and/or secondary
assays and will notify NeoGenesis of any active compounds (each, a PRIMARY
ACTIVE COMPOUND) within [*] after completion of such assays and not later than
[*] after the discrete compounds are delivered by NeoGenesis. NeoGenesis will
prepare a report for all Primary Active Compound(s) that details the
structure(s), binding affinities, Target specificity(ies), and functional
activities of such Primary Active Compound (each, an FINAL TARGET REPORT).
NeoGenesis will prepare such report following notice from OGS of the Primary
Active Compounds but may deliver a report based upon the discrete compounds if
OGS does not provide notice of the Primary Active Compounds within the
applicable time period. In this case, such discrete compound report will serve
as the Final Target Report.

5. If requested by the Steering Committee, NeoGenesis will provide further
evaluation of Primary Active Compounds to determine the Kd value, and will
perform competition experiments between such Primary Active Compounds.

6. OGS may select up to [*] Primary Active Compounds per Target, for further
study or optimization (each, a SELECTED COMPOUND). NeoGenesis will provide OGS
with [*] of up to [*] Selected Compound(s) for further evaluation by OGS in
Target-based secondary assays. In the event that OGS wishes to have NeoGenesis
provide additional quantities of Selected Compounds and the work necessary to
prepare such materials will exceed the budgeted FTE commitment for such period,
the parties shall negotiate a separate fee for such work, which will be based
upon FTE rate and which shall be billed separately by NeoGenesis.

7. At the request of OGS, NeoGenesis will perform Kd-driven optimization on each
Selected Compound identified by OGS. To perform such optimization, NeoGenesis
will create NeoMorph Focused Libraries based upon such Selected Compounds and
will perform high stringency-ALIS screening to improve Kd values to [*]
micromolar

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

or better (i.e., Kd LESS THAN OR EQUAL TO [*]). In the event that such work
will exceed the budgeted FTE commitment for such period, the parties shall
negotiate a separate fee for such work, which will be based upon FTE rate and
which shall be billed separately by NeoGenesis.

8. NeoGenesis will dedicate ALIS resources to the Program for [*] target weeks
per year of screening to the Program, with the distribution of screening time
per Target to be defined for each individual Target through the Steering
Committee. The anticipated timeframe for the performance of the Program with
respect to each Target that NeoGenesis accepts pursuant to Section 2.1 is as
indicated on the diagram attached as ATTACHMENT A1 to this ATTACHMENT A.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

                                  ATTACHMENT B
                          PROGRAM INTELLECTUAL PROPERTY
                          [TO BE SUPPLIED AS DEVELOPED]

                                  ATTACHMENT C
                                     TARGETS
         [TO BE SUPPLIED BY OGS AFTER FIRST STEERING COMMITTEE MEETING]

                                  ATTACHMENT D
                            NEOGENESIS PATENT RIGHTS
                  [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

                               NEOGENESIS KNOW-HOW
                         [TO BE SUPPLIED AS APPLICABLE]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]